Patent Publication Number: US-2013243764-A1

Title: Antigen-binding proteins with increased fcrn binding

Description:
FIELD 
     The invention relates to novel variants of anti-TNF antibodies. 
     BACKGROUND 
     Antibodies are heteromultimeric glycoproteins comprising at least two heavy and two light chains. Aside from IgM, intact antibodies are usually heterotetrameric glycoproteins of approximately 150 Kda, composed of two identical light (L) chains and two identical heavy (H) chains. Each heavy chain has at one end a variable domain (VH) followed by a number of constant regions. Each light chain has a variable domain (VL) and a constant region at its other end; the constant region of the light chain is aligned with the first constant region of the heavy chain and the light chain variable domain is aligned with the variable domain of the heavy chain. Depending on the amino acid sequence of the constant region of their heavy chains, human antibodies can be assigned to five different classes, IgA, IgD, IgE, IgG and IgM. IgG and IgA can be further subdivided into subclasses, IgG1, IgG2, IgG3 and IgG4; and IgA1 and IgA2. The variable domain of the antibody confers binding specificity upon the antibody with certain regions displaying particular variability called complementarity determining regions (CDRs). The more conserved portions of the variable region are called Framework regions (FR). The variable domains of intact heavy and light chains each comprise four FR connected by three CDRs. The constant regions are not directly involved in the binding of the antibody to the antigen but exhibit various effector functions such as participation in antibody dependent cell-mediated cytotoxicity (ADCC), phagocytosis via binding to Fcγ receptor, half-life/clearance rate via neonatal Fc receptor (FcRn) and complement dependent cytotoxicity via the C1q component of the complement cascade. The nature of the structure of an IgG antibody is such that there are two antigen-binding sites, both of which are specific for the same epitope. They are therefore, monospecific. 
     In adult mammals, FcRn, also known as the neonatal Fc receptor, plays a key role in maintaining serum antibody levels by acting as a protective receptor that binds and salvages antibodies of the IgG isotype from degradation. IgG molecules are endocytosed by endothelial cells, and if they bind to FcRn, are recycled out into circulation. In contrast, IgG molecules that do not bind to FcRn enter the cells and are targeted to the lysosomal pathway where they are degraded. 
     The neonatal FcRn receptor is believed to be involved in both antibody clearance and the transcytosis across tissues (see Junghans R. P (1997) Immunol. Res 16. 29-57 and Ghetie et al (2000) Annu. Rev. Immunol. 18, 739-766). 
     WO 9734631 discloses a composition comprising a mutant IgG molecule having increased serum half-life and at least one amino acid substitution in the Fc-hinge region. Amino acid substitution at one or more of the amino acids selected from number 252, 254, 256, 309, 311 or 315 in the CH2 domain or 433 or 434 in the CH3 domain is disclosed. 
     WO 00/42072 discloses a polypeptide comprising a variant Fc region with altered FcRn binding affinity, which polypeptide comprises an amino acid modification at any one or more of amino acid positions 238, 252, 253, 254, 255, 256, 265, 272, 286, 288, 303, 305, 307, 309, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 386, 388, 400, 413, 415, 424, 433, 434, 435, 436, 439, and 447 of the Fc region. 
     WO 02/060919 discloses a modified IgG comprising an IgG constant domain comprising amino acid modifications at one or more of positions 251, 253, 255, 285-290, 308-314, 385-389, and 428-435. 
     WO 2004035752 discloses a modified antibody of class IgG wherein at least one amino acid residue from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is different from that present in an unmodified class IgG antibody. 
     Shields et al. (2001, J Biol Chem; 276:6591-604) used alanine scanning mutagenesis to alter residues in the Fc region of a human IgG1 antibody and then assessed the binding to human FcRn. Positions that effectively abrogated binding to FcRn when changed to alanine include 1253, S254, H435, and Y436. Other positions showed a less pronounced reduction in binding as follows: E233-G236, R255, K288, L309, S415, and H433. Several amino acid positions exhibited an improvement in FcRn binding when changed to alanine. 
     Dall&#39;Acqua et al. (2002, J Immunol.; 169:5171-80) described random mutagenesis and screening of human IgG1 hinge-Fc fragment phage display libraries against mouse FcRn. They disclosed random mutagenesis of positions 251, 252, 254-256, 308, 309, 311, 312, 314, 385-387, 389, 428, 433, 434, and 436. 
     WO2006130834 discloses modified IgG comprising an IgG comprising an IgG constant domain comprising amino acid modifications at one or more positions of 252, 254, 256, 433, 434 and 436. 
     Therefore, modification of Fc domains of IgG antibodies has been discussed as a means of increasing the serum half-life of therapeutic antibodies. However, numerous such modifications have been suggested with varying and sometimes contradictory results in different antibodies. 
     The administration of antigen binding proteins as therapeutics requires injections with a prescribed frequency relating to the clearance and half-life characteristics of the protein. 
     Adalimumab is a monoclonal antibody against TNF-alpha which is used for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn&#39;s disease. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 330 amino acids and has a molecular weight of approximately 148 kilodaltons. See U.S. Pat. No. 6,090,382. At doses of 0.5 mg/kg (˜40 mg), clearance for adalimumab is said to range from 11 to 15 ml/hour, the distribution volume (V ss ) ranges from 5 to 6 litres and the mean terminal phase half-life was approximately two weeks (Summary of Product Characteristics available from www.medicines.org.uk). These half life and clearance properties mean that currently adalimumab needs to be administered once every two weeks. In some patients depending on disease it may be necessary to administer a loading dose such as for example in psoriasis patients. This dosage may differ from the maintenance dose. 
     SUMMARY OF INVENTION 
     In one aspect, the invention relates to an antigen binding protein which specifically binds to TNF-alpha comprising CDRH1 (SEQ ID NO: 27), CDRH2 (SEQ ID NO: 28), CDRH3 (SEQ ID No: 29), CDRL1 (SEQ ID NO: 30), CDRL2 (SEQ ID NO: 31), and CDRL3 (SEQ ID NO: 32) or variants thereof wherein said variants may contain 1, 2, 3 or 4 amino acid substitutions, insertions or deletions as compared to CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3; and a neonatal Fc receptor (FcRn) binding portion of a human IgG1 constant domain comprising one of more amino acid substitutions relative to the human IgG1 constant domain, wherein the antigen binding protein has an increased FcRn binding affinity at pH 6 and/or increased half-life as compared to an IgG comprising the light chain sequence of SEQ ID No. 2 and the heavy chain sequence of SEQ ID No.12. 
     Throughout the specification the term “human IgG1 constant domain” encompasses all allotypes and variants thereof known to a person skilled in the art. 
     In one aspect, the invention relates to an antigen binding protein which specifically binds to TNF-alpha comprising CDRH1 (SEQ ID NO: 27), CDRH2 (SEQ ID NO: 28), CDRH3 (SEQ ID No: 29), CDRL1 (SEQ ID NO: 30), CDRL2 (SEQ ID NO: 31), and CDRL3 (SEQ ID NO: 32); or variants thereof wherein said variants may contain 1, 2, 3 or 4 amino acid substitutions, insertions or deletions as compared to CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3; and a neonatal Fc receptor (FcRn) binding portion of a human IgG1 constant domain comprising one of more amino acid substitutions relative to the human IgG1 constant domain, wherein the antigen binding protein has an increased half life as compared to an IgG comprising the light chain sequence of SEQ ID No. 2 and heavy chain sequence of SEQ ID No.12 and the antigen binding protein can be administered no more than once every four weeks to achieve comparable mean steady-state trough concentration as that achieved by the same dose of IgG comprising the light chain sequence of SEQ ID No. 2 and the heavy chain sequence of SEQ ID No.12 administered once every two weeks. 
     In one aspect, the invention relates to an antigen binding protein which specifically binds to TNF-alpha comprising CDRH1 (SEQ ID NO: 27), CDRH2 (SEQ ID NO: 28), CDRH3 (SEQ ID No: 29), CDRL1 (SEQ ID NO: 30), CDRL2 (SEQ ID NO: 31), and CDRL3 (SEQ ID NO: 32) or variants thereof wherein said variants may contain 1, 2, 3 or 4 amino acid substitutions, insertions or deletions as compared to CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3; and an FcRn binding portion of a human IgG1 constant domain comprising one of more amino acid substitutions relative to the human IgG1 constant domain, wherein the antigen binding protein has an affinity for FcRn of 2 fold, or 3 fold, or 4 fold or 5 fold, or 6 fold or 8 fold or greater than an anti-TNF antigen binding protein with the same CDR&#39;s without such modifications at pH 6 as assessed by PrateOn XPR36 protein interaction array system at 25° C., the array system having antigen binding proteins immobilised on the chip. 
     In one aspect, the invention relates to an antigen binding protein which is a variant of an IgG comprising the light chain sequence of SEQ ID No. 2 and the heavy chain sequence of SEQ ID No.12, wherein the antigen binding protein variant comprises one or more substitutions in the neonatal Fc receptor (FcRn) binding portion of the IgG constant domain to increase the half-life of the antigen binding protein variant compared with the IgG without such substitutions, wherein when the variant is administered to patients at a single dose of 40 mg at a four to eight weekly interval, the mean steady-state trough concentration in the patient population does not fall below 4 μg/ml or does not fall below 5 μg/ml between dosing intervals. Preferably, the mean serum trough antibody concentration in the patient population does not fall below 6 μg/ml between dosing intervals. Preferably, the mean serum trough antibody concentration in the patient population does not fall below 5 μg/ml between dosing intervals when the variant is administered to patients at a single dose of 40 mg at an eight weekly interval. Preferably, the mean serum trough antibody concentration in the patient population does not fall below 4 μg/ml between dosing intervals whilst still providing the optimal efficacy when the variant is administered to patients at a single dose of 40 mg at an eight weekly interval. Preferably, the mean serum trough antibody concentration in the patient population does not fall below 3 μg/ml between dosing intervals whilst still providing the optimal efficacy when the variant is administered to patients at a single dose of 40 mg at an eight weekly interval. 
     In one aspect, the invention relates to an antigen binding protein as disclosed herein for treatment of a disease wherein the antigen binding protein can be administered to patients no more than once every four weeks to achieve comparable mean steady-state trough concentration as that achieved by the same dose of an IgG comprising light chain sequence of SEQ ID No. 2 and heavy chain sequence of SEQ ID No.12 administered once every two weeks. 
     In one aspect, the invention relates to a method of treating a patient with a disease, the method comprising administering an antigen binding protein according to the invention. 
     In one aspect, the invention relates to a nucleic acid sequence encoding the antigen binding protein according to the invention, or a part thereof such as a heavy or light chain. In one aspect, the invention relates to an expression vector encoding the antigen binding protein according to the invention, or a part thereof such as a heavy or light chain. 
     In one aspect, the invention relates to a host cell comprising the nucleic acid sequence encoding the antigen binding protein according to the invention. In one aspect, the invention relates to an antigen binding protein according to the invention for use in the treatment of Psoriasis or rheumatoid arthritis. 
     In one aspect, the invention relates to a kit comprising the antigen binding protein according to the invention, and optionally comprising methotrexate for concomitant delivery of antigen binding protein according to the invention and methotrexate. 
     In one aspect, the invention relates to an antigen binding protein as disclosed herein for treatment of Rheumatoid arthritis in an individual who is already being treated with methotrexate, and to an antigen binding protein in combination with methotrexate for treatment of Rheumatoid arthritis, wherein the combination is delivered simultaneously, substantially simultaneously, or sequentially. 
     In one aspect, the invention relates to an antigen binding protein as disclosed herein for treatment of Psoriasis in an individual who is already being treated with methotrexate, and to an antigen binding protein in combination with methotrexate for treatment of Psoriasis, wherein the combination is delivered simultaneously, substantially simultaneously, or sequentially. 
    
    
     
       BRIEF DESCRIPTION OF FIGURES 
       FIG.  1 —Binding of anti-TNFα antibodies to human TNFα 
       FIG.  2 —Analysis of binding activity of anti-TNFα antibodies to human TNFα following an accelerated stressor study 
       FIG.  3 —Binding of anti-TNFα antibodies to human TNFα following incubation in 25% human serum for 2 weeks 
       FIG.  4 —Binding of anti-TNFα antibodies to human TNFα following freeze-thaw 
       FIG.  5 —Analysis of anti-TNFα antibodies to FcγRIIIa receptors (a) Binding to human FcγRIIIa (valine 158 variant) (b) Binding to human FcγRIIIA (phenylalanine 158 variant) 
       FIG.  6 —Average dose normalised plasma concentrations of BPC2604 in female cynomolgus monkeys and pascolizumab in male cynomolgus monkeys following a single intravenous (1 hr infusion) 
     
    
    
     DETAILED DESCRIPTION OF INVENTION 
     The invention relates to novel antigen binding proteins binding specifically to TNF-alpha. In particular, the invention relates to novel variants of anti-TNF antibodies such as adalimumab which show increased binding to the FcRn receptor and/or increased half life as compared to adalimumab. Adalimumab is an IgG monoclonal antibody comprising the light chain sequence of SEQ ID No. 2 and heavy chain sequence of SEQ ID No.12. 
     The inventors have found that specific modifications to adalimumab as described herein show particular improvements in FcRn binding as shown in the examples below. Affinity matured variants of adalimumab also show improvement in anti-TNF-alpha binding and/or neutralisation activity. 
     The novel antigen binding proteins of the invention have an increased binding to the FcRn receptor and/or increased half life and/or increased Mean Residence Time and/or decreased Clearance. It is considered that binding to FcRn results in longer serum retention in vivo. In order to increase the retention of the Fc proteins in vivo, the increase in binding affinity is observed around pH 6. In one aspect, the present invention therefore provides an antigen binding protein with optimised binding to FcRn. 
     In one embodiment, the half-life of the antigen binding protein of the present invention is increased 2 to 6 fold, such as 2 fold, 3 fold, 4 fold, 5 fold or 6 fold as compared to an IgG comprising the light chain sequence of SEQ ID No. 2 and heavy chain sequence of SEQ ID No.12. Preferably, the half-life of the antigen binding protein of the invention is increased 3 fold, 4 fold, or more compared to an IgG comprising the light chain sequence of SEQ ID No. 2 and heavy chain sequence of SEQ ID No.12. For example, if the IgG is adalimumab having a half life of 10 days or in the range of 10 to 20 days then in one embodiment an antigen binding protein of the present invention shows a half life of about 40 to 80 days. For example an antigen binding protein comprising a heavy chain sequence selected from SEQ ID NO:5 or SEQ ID NO:9 or SEQ ID NO:15 or SEQ ID NO:18. or SEQ ID NO:21. or SEQ ID NO:24 or SEQ ID NO:163, or SEQ ID NO:165, or SEQ ID NO:167, or SEQ ID NO:169. 
     In one embodiment, the antigen binding protein of the invention administered no more than once every four weeks in patients, achieves mean steady-state trough concentrations between about 2 μg/ml to about 7 μg/ml. Preferably, the mean steady-state trough concentrations are between about 4 μg/ml to about 7 μg/ml and more preferably between about 5 μg/ml to about 6 μg/ml. 
     In one embodiment, the antigen binding protein of the invention administered no more than once every 28 days in patients, achieves mean steady-state trough concentrations between about 2 μg/ml to about 7 μg/ml. Preferably, the mean steady-state trough concentrations are between about 4 μg/ml to about 7 μg/ml and more preferably between about 5 μg/ml to about 6 μg/ml. 
     In one embodiment of the invention, the antigen binding protein of the invention can be administered once every 4, 5, 6, 7 or 8 weeks to achieve comparable mean steady-state trough concentrations as those achieved by adalimumab, when administered once every two weeks at the same dose. 
     In a preferred embodiment of all aspects of the invention, the antigen binding protein of the invention can be administered once every 7 or 8 weeks. 
     In one embodiment of the invention, the antigen binding protein of the invention can be administered once every 25-80 days for example once every 40-60 days, or for example once every 28, 35, 42, 49 or 56 days to achieve comparable mean steady-state trough concentrations as those achieved by adalimumab, when administered once every 14 days at the same dose. 
     In one embodiment of the invention, the antigen binding protein can be administered once every 49 to 60 day, for example every 56 days. 
     In an embodiment of all aspects of the invention, the antigen binding protein has a 2 fold, or 4 fold, or 6 fold, or 8 fold or greater affinity for human FcRn at pH 6 as assessed by PrateOn XPR36 protein interaction array system at 25° C. wherein the antibodies are immobilised on the chip. Preferably, the antigen binding protein has an affinity for human FcRn between about 100 to about 500 KD (nM), such as between about 130 to about 360 KD (nM) or between about 140 to about 250 KD (nM) or between about 140 to about 210 KD (nM). 
     In one embodiment, the clearance of the antigen binding protein is about 2 to about 10 ml/hr, preferably about 2 to about 5 ml/hr or 2 to 4 ml/hr or 2 to 3 ml/hr, such as about 2, about 2.5, 3, 4 or 5 ml/hr. In one embodiment the antigen binding protein of the invention shows a clearance rate which is 2 fold, 3 fold, 4 fold or 5 fold lower than adalimumab. In one embodiment, clearance for an antigen binding protein according to the invention is in the ranges specified above or 2 fold, 3 fold, 4 fold or 5 fold lower than adalimumab at a human dose of about 40 mg. 
     In one aspect, the antigen binding protein of the invention is a variant of adalimumab (IgG comprising the light chain sequence of SEQ ID No. 2 and the heavy chain sequence of SEQ ID No.12), the variant comprising one or more substitutions in the FcRn binding portion of the IgG constant domain to increase the half-life of the variant compared with adalimumab, wherein when the variant is administered to patients at a single dose of 40 mg at a four to eight weekly interval, preferably eight weekly interval, the mean steady-state trough antibody concentration in the patient population does not fall below 5 μg/ml. In one embodiment the mean steady-state trough antibody concentration in the patient population does not fall below 6 μg/ml, between dosing intervals. 
     In a further embodiment, the antigen binding protein comprises at least one amino acid modification in the Fc region of said antigen binding protein, wherein said modification is at one or more of positions 250, 252, 254, 256, 257, 259, 308, 428 or 434 of the Fc region as compared to same position in the adalimumab sequence, wherein the numbering of the amino acids in the Fc region is that of the EU index in Kabat. 
     The wild type human IgG1 has amino acid residues Val-Leu-His-Gln-Asp-Trp-Leu at positions 308-314, amino acid residues Leu-Met-Ile-Ser-Arg-Thr at positions 251-256, amino acid residues Met-His-Glu-Ala-Leu-His-Asn-HisTyr at positions 428-436, and amino acid residues Gly-Gln-Pro-Glu-Asn at positions 385-389. Residue numbering may differ for IgG2-4. 
     In one embodiment, the antigen binding protein of the invention comprises one or more amino acid substitution relative to the human IgG1 constant domain comprising the sequence of SEQ ID No. 13. 
     In one embodiment, the one or more amino acid substitution in the FcRn binding portion of the human IgG1 heavy chain constant domain is at amino acid residues 252, 254 and 256 numbered according to EU index of Kabat and the aa substitution at residue 252 is a substitution of met with tyr, phe, tryp or thr; the aa substitution at residue 254 is a substitution of ser with thr; and the aa substitution at residue 256 is a substitution of thr with ser, arg, glu, asp or thr. Preferably, the aa substitution at residue 252 is a substitution with tyr; the aa substitution at residue 254 is a substitution with thr and the substitution at residue 256 is a substitution with glu. Preferably, the IgG1 constant domain is as shown in SEQ ID No: 7. 
     In one embodiment, the one or more amino acid substitutions in the FcRn binding portion of the human IgG1 constant domain is at amino acid residues 250 and 428 numbered according to EU index of Kabat and the aa substitution at residue 250 is a substitution of thr with glu or gln; the aa substitution at residue 428 is a substitution of met with leu or phe. Preferably, the aa substitution at residue 250 is a substitution with glu and the aa substitution at residue 428 is a substitution with leu. Preferably, the IgG1 constant domain is as shown in SEQ ID No: 16. 
     In one embodiment, the one or more amino acid substitution in the FcRn binding portion of the human IgG1 constant domain is at amino acid residues 428 and/or 434 numbered according to EU index of Kabat. Preferably, the aa substitution at residue 428 is a substitution of met with leu and the aa substitution at residue 434 is a substitution of asn with ser. Preferably, the IgG1 constant domain is as shown in SEQ ID No: 10. 
     In one embodiment, the one or more amino acid substitution in the FcRn binding portion of the human IgG1 constant domain is at amino acid residues 259 or 308 numbered according to EU index of Kabat. Preferably, the substitution at residue 259 is a substitution of val with ile and the aa substitution at residue 308 is a substitution of val with phe. Preferably, the IgG1 constant domain is as shown in SEQ ID No: 19 or SEQ ID No: 22. 
     In one embodiment, the one or more amino acid substitution in the FcRn binding portion of the human IgG1 heavy chain constant domain is at amino acid residues 257 and 434 numbered according to EU index of Kabat as shown in SEQ ID No: 25. 
     In one embodiment, the one or more amino acid substitution in the FcRn binding portion of the human IgG1 heavy chain constant domain is at amino acid residues 433 and 434 numbered according to EU index of Kabat for example the residues are H433K and N434F Preferably, the IgG1 constant domain is as shown in SEQ ID No: 165 or SEQ ID No: 167. 
     In one embodiment, the antigen binding protein comprises any of the IgG1 constant domain modifications listed in Table A. 
     In one embodiment, the antigen binding protein is an antibody. 
     In one embodiment, the antigen binding protein comprises a variable domain of SEQ ID NO: 6 and/or SEQ ID NO: 3 or a variant thereof which contains 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, insertions or deletions and/or shares at least 90% identity across the length of SEQ ID NO: 6 or SEQ ID NO: 3. 
     In one embodiment, the antigen binding protein comprises the heavy chain sequence as shown in SEQ ID No 5, 9 or 15 optionally with a light chain sequence as shown in SEQ ID No: 2. 
     In one embodiment, the antigen binding protein comprises a variable heavy domain sequence as shown in SEQ ID NO: 78 or 80. 
     In one embodiment, the antigen binding protein comprises a heavy chain sequence as shown in SEQ ID NO: 145 or SEQ ID NO: 146 optionally with a light chain variant as shown in SEQ ID Nos. 148, 150 or 152. 
     In one embodiment, the antigen binding protein comprises the heavy chain sequence as shown in SEQ ID No 18 or 21 optionally with a light chain sequence as shown in SEQ ID No: 2. 
     In one embodiment the antigen binding protein according to the invention comprises any of the variable domains specified in Table A. In one embodiment, the antigen binding protein according to the invention comprises the variable heavy domain having the sequence of cb1-3-VH, cb2-44-VH, cb1-39-VH, cb1-31-VH, cb2-11-VH, cb2-40-VH, cb2-35-VH, cb2-28-VH, cb2-38-VH, cb2-20-VH, cb1-8-VL or cb1-43-VL as shown in Table A. 
     In one embodiment, the antigen binding protein according to the invention comprises the variable light domain having the sequence of cb1-45-VL, cb1-4-VL, cb1-41-VL, cb1-37-VL, cb1-39-VL, cb1-33-VL, cb1-35-VL, cb1-31-VL, cb1-29-VL, cb1-22-VL, cb1-23-VL, cb1-12-VL, cb1-10-VL, cb2-1-VL, cb2-11-VL, cb2-40-VL, cb2-35-VL, cb2-28-VL, cb2-20-VL, cb1-3-VL, cb2-6-VL or cb2-44-VL as shown in Table A. 
     For example, the antigen binding protein according to the invention comprises a variable domain having the sequence of cb1-3VH, cb2-44VH or cb2-6VL as shown in Table A. 
     In one embodiment the antigen binding protein according to the invention comprises any of the variable domains specified in Table A. In one embodiment, the antigen binding protein according to the invention comprises the variable heavy domain having a sequence selected from SEQ ID NO: 170 or SEQ ID NO: 174 or SEQ ID NO:178 
     In one embodiment, the antigen binding protein according to the invention comprises the variable light domain having a sequence selected from SEQ ID NO: 171 or SEQ ID NO: 175 or SEQ ID NO:179 
     In a further embodiment the antigen binding protein comprises any of the IgG1 constant domain modifications listed in Table A. 
     Variants of all the above mentioned variable domains or heavy chain sequences or light chain sequences which contain 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, insertions or deletions and/or share at least 90% identity across the length of any of these sequences are also within the scope of the invention. 
     In one embodiment, the antigen binding protein of the invention comprises a variant of CDRH3 (SEQ ID No: 29) which variant has 1, 2, 3 or 4 amino acid substitutions as compared to SEQ ID No: 29. In one embodiment, the variant CDRH3 may have the sequence as shown in any one of SEQ ID Nos. 40 to 49. 
     In one embodiment, the antigen binding protein of the invention comprises a variant of CDRH1 (SEQ ID No: 27) which variant has 1 or 2 amino acid substitutions as compared to SEQ ID No: 27. In one embodiment, the variant CDRH1 may have the sequence as shown in any one of SEQ ID Nos. 33 to 38. 
     In one embodiment, the antigen binding protein of the invention comprises a variant of CDRL1 (SEQ ID No: 30) which variant has 1, 2 or 3 amino acid substitutions as compared to SEQ ID No: 30. In one embodiment, the variant CDRL1 may have the sequence as shown in any one of SEQ ID Nos. 50 to 61. 
     In one embodiment, the antigen binding protein of the invention comprises a variant of CDRL2 (SEQ ID No: 31) which variant has 1, 2 or 3 amino acid substitutions as compared to SEQ ID No: 31. In one embodiment, the variant CDRL2 may have the sequence as shown in any one of SEQ ID Nos. 62 to 72. 
     In one embodiment, the antigen binding protein of the invention comprises a variant of CDRL3 (SEQ ID No: 32) which variant has 1, 2 or 3 amino acid substitutions as compared to SEQ ID No: 32. In one embodiment, the variant CDRL3 may have the sequence as shown in any one of SEQ ID Nos. 73 to 76. 
     In one embodiment, the invention relates to an antigen binding protein which specifically binds to TNF-alpha comprising one or more or all CDRs selected from: CDRH1 (SEQ ID NO: 27), CDRH2 (SEQ ID NO: 28), CDRH3 (SEQ ID No: 29), CDRL1 (SEQ ID NO: 30), CDRL2 (SEQ ID NO: 31), and CDRL3 (SEQ ID NO: 32); wherein any of the CDRs could be a variant CDR which contains 1, 2, 3 or 4 amino acid substitutions, insertions or deletions as compared to CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3. In one aspect, the antigen binding protein of the invention comprises CDRH1, CDRH3, CDRL1, CDRL2 and CDRL3 wherein any of the CDRs could be a variant CDR which contains 1, 2, 3 or 4 amino acid substitutions, insertions or deletions compared to CDRH1, CDRH3, CDRL1, CDRL2, or CDRL3. In one aspect, the antigen binding protein of the invention comprises CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 wherein any of the CDRs could be a variant CDR which contains 1, 2, 3 or 4 amino acid substitutions, insertions or deletions compared to CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, or CDRL3 
     In one aspect, the invention relates to a method of treating a human patient with a disease, the method comprising administering an antigen binding protein according to the invention. 
     The invention also relates to an antigen binding protein as disclosed herein for the treatment of disease in a human. 
     The invention also relates to use of an antigen binding protein as disclosed herein in the manufacture of a medicament for the treatment of disease, and an antigen binding protein as disclosed herein for use in treatment of disease. 
     In one embodiment, the disease to be treated by the antigen binding protein of the invention is rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Ulcerative colitis, spondyloarthropathy, Crohn&#39;s disease or Psoriasis. 
     In one embodiment, the antigen binding protein of the invention is to be administered with methotrexate. The methotrexate can be delivered before, after or at the same time, or substantially the same time, as the antigen binding protein. In a preferred embodiment the antigen binding protein of the invention is to be administered with methotrexate to a patient suffering from rheumatoid arthritis. In one embodiment, methotrexate is administered to patients receiving an antigen binding protein of the invention to reduce the immunogenic effect of the antigen binding protein. In one embodiment, the antigen binding protein of the invention is administered to patients already receiving methotrexate. Methotrexate may be substituted by another acceptable compound which reduced the immune response to the antigen binding protein, for example corticosteroids. 
     In one aspect, the invention relates to a method of treating a patient with a disease, the method comprising administering an antigen binding protein of the invention. In one embodiment, the method comprises administering an antigen binding protein to the patient as a single 20, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 mg dose no more than once every four weeks, preferably once every 5, 6, 7, or 8 weeks and most preferably once every 8 weeks. Preferably, the dose is 40 to 80 mg, for example 40 mg. 
     The invention also provides a polynucleotide sequence encoding any amino acid sequence disclosed herein, including a heavy chain of any of the antigen binding constructs described herein, and a polynucleotide encoding a light chain of any of the antigen binding constructs described herein. Such polynucleotides represent the coding sequence which corresponds to the equivalent polypeptide sequences, however it will be understood that such polynucleotide sequences could be cloned into an expression vector along with a start codon, an appropriate signal sequence and a stop codon. The polynucleotide may be DNA or RNA. 
     The invention also provides a host cell, for example a recombinant, transformed or transfected cell, comprising one or more polynucleotides encoding a heavy chain and/or a light chain of any of the antigen binding constructs described herein. 
     The invention further provides a pharmaceutical composition comprising an antigen binding construct as described herein a pharmaceutically acceptable carrier. 
     The invention further provides a method for the production of any of the antigen binding constructs described herein which method comprises the step of culturing a host cell comprising a first and second vector, said first vector comprising a polynucleotide encoding a heavy chain of any of the antigen binding constructs described herein and said second vector comprising a polynucleotide encoding a light chain of any of the antigen binding constructs described herein, in a serum-free/chemically defined/animal derived component free culture media. Alternatively a method may comprise culturing a host cell comprising a vector comprising a polynucleotide encoding a heavy chain of any of the antigen binding constructs described herein and a polynucleotide encoding a light chain of any of the antigen binding constructs described herein, suitably in a serum-free/chemically defined/animal derived component free culture media. 
     In another embodiment, the invention includes a method of increasing the half-life of an antibody by modifying an Fc according to the modifications described herein. 
     In another embodiment, the invention includes an antigen binding protein as described herein with enhanced FcRn binding and having one or more additional substitutions, deletions or insertions that modulate another property of the effector function. 
     Once expressed by the desired method, the antigen binding protein of the invention is then examined for in vitro activity by use of an appropriate assay. Presently conventional ELISA and Biacore assay formats are employed to assess qualitative and quantitative binding of the antigen binding construct to its target. Additionally, other in vitro assays may also be used to verify neutralizing efficacy prior to subsequent human clinical studies performed to evaluate the persistence of the antigen binding protein in the body despite the usual clearance mechanisms. 
     The dose and duration of treatment relates to the relative duration of the molecules of the present invention in the human circulation, and can be adjusted by one of skill in the art depending upon the condition being treated and the general health of the patient based on the information provided herein. It is envisaged that repeated dosing (e.g. once every 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks) over an extended time period (e.g. four to six months) maybe required to achieve maximal therapeutic efficacy. 
     The mode of administration of the therapeutic agent of the invention may be any suitable route which delivers the agent to the host. The antigen binding proteins, and pharmaceutical compositions of the invention are particularly useful for parenteral administration, i.e., subcutaneously (s.c.), intrathecally, intraperitoneally, intramuscularly (i.m.), intravenously (i.v.), or intranasally. In one embodiment the antigen binding proteins and pharmaceutical compositions of the invention are administered via a subcutaneous auto injector pen or a subcutaneous pre-filled syringe. 
     Antigen binding proteins of the invention may be prepared as pharmaceutical compositions containing an effective amount of the antigen binding protein of the invention as an active ingredient in a pharmaceutically acceptable carrier. In the prophylactic agent of the invention, an aqueous suspension or solution containing the antigen binding construct, preferably buffered at physiological pH, in a form ready for injection is preferred. The compositions for parenteral administration will commonly comprise a solution of the antigen binding construct of the invention or a cocktail thereof dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be employed, e.g., 0.9% saline, 0.3% glycine, and the like. These solutions may be made sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc. The concentration of the antigen binding protein of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., according to the particular mode of administration selected. 
     It has been reported that adalimumab is difficult to formulate at high concentrations. WO2004016286 describes an adalimumab formulation comprising a citrate-phosphate buffer and other components including a polyol and a detergent. The oral presentation “Humira®—from Development to Commercial Scale Production” presented on 25 Oct. 2005 at the PDA Conference reports formulations comprising (i) citrate-phosphate buffer; (ii) acetate-phosphate buffer; and (iii) phosphate buffer. The acetate-phosphate buffer tested displayed the worst stabilising effect upon adalimumab. Curtis et al. (2008) Current Medical Research and Opinion, Volume 27, p 71-78, report the incidence of injection-site burning and stinging in patients with rheumatoid arthritis using injectable adalimumab. The burning and stinging has been partly attributed to citrate buffer-based formulations (Basic and Clinical Pharmacology &amp; Toxicology, Volume 98, p 218-221, 2006; and Journal of Pharmaceutical Sciences, Volume 97, p 3051-3066, 2008). However, WO20100129469 describes a high adalimumab concentration formulation that still comprises a citrate-phosphate buffer and other components including a polyol with no sodium chloride. The more recent WO2012065072 describes an adalimumab formulation comprising a surfactant and a polyol with no buffer, thus potentially avoiding any citrate buffer effects upon injection. 
     In one embodiment there is provided a liquid formulation comprising a TNF-alpha antigen binding protein and an acetate buffer. In a further embodiment the TNF-alpha binding protein comprises a CDRH1 selected from SEQ ID NO:27 or SEQ ID NO:&#39;s 33-38 and/or a CDRH2 of SEQ ID NO:28 and/or a CDRH3 selected from SEQ ID NO:29 or SEQ ID NO:&#39;s 40-49 and/or a CDRL1 selected from SEQ ID NO:30 or SEQ ID NO:&#39;s 50-61 and/or a CDRL2 selected from SEQ ID NO:31 or SEQ ID NO:&#39;s 62-72 and/or a CDRL3 of SEQ ID NO:32 or SEQ ID NO:&#39;s73-76. For example the TNF-alpha antigen binding protein comprises CDRH1 of SEQ ID NO:27 and CDRH2 of SEQ ID NO:28 and CDRH3 of SEQ ID NO:29 and CDRL1 of SEQ ID NO:30 and CDRL2 selected from SEQ ID NO:31 and a CDRL3 of SEQ ID NO:32 or variants thereof. 
     The TNF-alpha antigen binding protein may be adalimumab. The TNF-alpha antigen binding protein may be BPC1494. The TNF-alpha antigen binding protein may be BPC 1496. 
     The TNF-alpha antigen binding proteins described herein are formulated in an acetate buffer. The formulation may be in liquid form. The formulation may further comprise one or more, a combination, or all of: a surfactant; a chelator; a salt; and an amino acid. The TNF-alpha antigen binding proteins are formulated at high concentrations, for example at 50 mg/mL. In one embodiment, the formulation does not comprise a polyol. In another embodiment, the formulation does not comprise a further buffer component, for example citrate. Therefore, the formulations described herein solve the problem of providing TNF-alpha antigen binding proteins, in particular the TNF-alpha antigen binding proteins as described in Table A, at high concentrations in a stable formulation, and avoid the burning and stinging effects of citrate-based buffers. 
     In one embodiment, the acetate buffer formulation further comprises a surfactant and a chelator. In another embodiment, the acetate buffer formulation further comprises a surfactant and a salt. In another embodiment, the acetate buffer formulation further comprises a surfactant and an amino acid. In another embodiment, the acetate buffer formulation further comprises a chelator and a salt. In another embodiment, the acetate buffer formulation further comprises a chelator and an amino acid. In another embodiment, the acetate buffer formulation further comprises a salt and an amino acid. 
     In one embodiment, the acetate buffer formulation further comprises a surfactant, a chelator, and a salt. In another embodiment, the acetate buffer formulation further comprises a surfactant, a chelator, and an amino acid. In another embodiment, the acetate buffer formulation further comprises a surfactant, a salt, and an amino acid. In another embodiment, the acetate buffer formulation further comprises a chelator, a salt, and an amino acid. 
     In one embodiment, the buffer is sodium acetate trihydrate. This may be at a concentration of 10 to 100 mM sodium acetate trihydrate (1.361 to 13.61 mg/mL). Sodium acetate trihydrate may be present in an amount of 20 to 80 mM, 30 to 70 mM, 40 to 60 mM, or about 40 mM, about 45 mM, about 50 mM, about 55 mM, or about 60 mM. In one embodiment, sodium acetate trihydrate is at a concentration of about 50 mM (6.80 mg/mL). 
     The acetate buffer may be the sole buffer. In other words, the formulation may not comprise another buffer component, such as phosphate or citrate buffer. Citrate buffer may be detrimental to the formulation for a number of reasons: (i) it may not be a good buffer because the values of the three dissociation constants are too close to permit distinction of the three proton receptor phases; (ii) citrate may act as a metal chelator and thus influence metal ion balance: (iii) citrate is a metabolite of the citric acid cycle and has the potential to influence cellular metabolism. 
     Suitable surfactants (also known as detergents) may include, e.g., polysorbates (for example, polysorbate 20 or 80), polyoxyethylene alkyl ethers such as Brij 35®, poloxamers (for example poloxamer 188, Poloxamer 407), Tween 20, Tween 80, Cremophor A25, Sympatens ALM/230, and Mirj. In one embodiment, the surfactant is polysorbate 80. The formulation may comprise a concentration of 0.01 to 0.1% polysorbate 80 (0.1 to 1 mg/mL). Polysorbate 80 may be present in an amount of 0.01 to 0.05%, or 0.01 to 0.03%; or about 0.015%, about 0.02%, or about 0.025%. In one embodiment, polysorbate 80 is at a concentration of about 0.02% w/v (0.2 mg/mL). A high concentration of polysorbate 80, for example more than 0.1%, may be detrimental to the formulation because this surfactant may contain high levels of oxidants which may increase levels of oxidation upon storage of the formulation and therefore reduce shelf life. 
     Suitable chelating agents may include EDTA and metal complexes (e.g. Zn-protein complexes). In one embodiment, the chelating agents is EDTA. The formulation may comprise a concentration of 0.02 to 0.2 mM EDTA (0.00748 to 0.0748 mg/mL). EDTA may be present in an amount of 0.02 to 0.15 mM, 0.02 to 0.1 mM, 0.03 to 0.08 mM, or 0.04 to 0.06 mM; or about 0.03 mM, about 0.04 mM, about 0.05 mM, or about 0.06 mM. In one embodiment, EDTA is at a concentration of about 0.05 mM (0.018 mg/mL). 
     Suitable salts may include any salt-forming counterions, such as sodium. For example, sodium chloride may be used, or anionic acetate instead of chloride as a counterion in a sodium salt may be used. In one embodiment, the salt is sodium chloride. The formulation may comprise a concentration of 25 to 100 mM sodium chloride (1.461 to 5.84 mg/mL). Sodium chloride may be present in an amount of 35 to 90 mM, 45 to 80 mM, 25 to 70 mM, or 45 to 60 mM; or 45 mM, 46 mM, 47 mM, 48 mM, 49 mM, 50 mM, 51 mM, 52 mM, 53 mM, 54 mM, 55 mM. In one embodiment, sodium chloride is at a concentration of about 51 mM (2.98 mg/mL). 
     Suitable amino acids may include arginine. The formulation may comprise a concentration of 0.5 to 5% arginine free base (5 to 50 mg/mL). Arginine free base may be present in an amount of In other embodiments, the arginine free base may be between 0.5 to 4.0%, 0.5 to 3.5%, 0.5 to 3.0%, 0.5 to 2.5%, or about 0.5%, about 0.75%, about 1%, about 1.5%, about 2%, or about 3%. In one embodiment, arginine is at a concentration of about 1% (10 mg/mL). 
     A polyol is a substance with multiple hydroxyl groups, and includes sugars (reducing and non-reducing sugars), sugar alcohols and sugar acids. Examples of polyols include fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, glucose, sucrose, trehalose, sorbose, melezitose, raffinose, mannitol, xylitol, erythritol, threitol, sorbitol, glycerol, L-gluconate and metallic salts thereof. In one embodiment, the formulation of the invention does not comprise a polyol. 
     In one embodiment, the acetate buffer formulation further comprises one or more, a combination, or all of: polysorbate 80, EDTA, sodium chloride, and arginine free base. 
     The pH of the formulation may be adjusted to pH 5.0 to 7.0. In one embodiment, acetic acid is present (about 100 mM acetic acid) to adjust the formulation to about pH 5.5. In other embodiments, the pH may be adjusted to pH 5.0, 5.5, 6.0, 6.5 or 7.0. In yet other embodiments of the invention, NaOH or HCl is used to adjust the pH to 5.0, 5.5, 6.0, 6.5 or 7.0. 
     The TNF-alpha antigen binding proteins described herein may be formulated in the concentration range of 20 to 300 mg/mL. For example, the antigen binding protein is present in a concentration of 20-200 mg/mL or 50-100 mg/mL; or about 40 mg/mL or about 45 mg/mL or about 50 mg/mL or about 55 mg/mL or about 60 mg/mL or about 70 mg/mL or about 80 mg/mL or about 90 mg/mL, or about 100 mg/mL. In one embodiment, the TNF-alpha antigen binding protein is at a concentration of about 50 mg/mL. 
     The TNF-alpha antigen binding protein may be adalimumab. The TNF-alpha antigen binding protein may be BPC1494. The TNF-alpha antigen binding protein may be BPC 1496. 
     In one embodiment, the formulation is stable for at least 1 year, at least 18 months, or at least 2 years. For example, the formulation is stable at a temperature of about 5° C. for at least 1 year, at least 18 months, or at least 2 years. In another embodiment, the formulation is stable at room temperature (about 25° C.). For example, the formulation is stable at a temperature of about 25° C. for at least 14 weeks, at least 2 weeks, at least 1 week, at least 6 days, at least 5 days, at least 4 days, at least 3 days, at least 2 days or at least 1 day. In another embodiment, the formulation is stable at a temperature of about 40° C. For example, the formulation is stable at a temperature of about 40° C. for at least 9 weeks or at least 4 weeks. 
     As shown by Examples 25 and 26 below, the formulations are stable at room temperature (about 25° C.). Therefore, there is minimal risk of aggregates or low molecular weight fragments forming in pre-filled devices for injection that may be left at room temperature for more than the recommended time. Aggregates are potentially immunogenic (see The AAPS Journal 2006; 8 (3) Article 59 Themed Issue: Proceedings of the 2005 AAPS Biotec Open Forum on Aggregation of Protein Therapeutics, Guest Editor—Steve Shire, Effects of Protein Aggregates: An Immunologic Perspective) and low molecular weight fragments may illicit pre-existing autoantibodies (see J Immunol 2008; 181:3183-3192; Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs1). 
     The stability of a TNF-alpha antigen binding protein in a liquid formulation may be assessed by any one or a combination of: appearance by visual observation, protein concentration (A280 nm), size exclusion chromatography (SEC), Capillary Iso-Electric Focussing (c-IEF), and by a functional binding assay (ELISA). For example, the percentage of monomer, aggregate, or fragment, or combinations thereof, can be used to determine stability. In one embodiment, a stable liquid formulation is a formulation having less than about 10%, or less than about 5% of the TNF-alpha antigen binding protein being present as aggregate in the formulation. The formulation may have a monomer content of at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. The formulation may have a monomer content of at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% at room temperature (about 25° C.) after about 2 weeks. The formulation may have a monomer content of at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% at room temperature (about 25° C.) after about 1 week. The formulation may have a monomer content of at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% at room temperature (about 25° C.) after about 1 day. 
     Thus, a pharmaceutical composition of the invention for injection could be prepared to contain 1 mL sterile buffered water, and between about 1 mg to about 100 mg, e.g. about 30 mg to about 100 mg or more preferably, about 35 mg to about 80 mg, such as 40, 50, 80 or 90 mg of an antigen binding construct of the invention. Actual methods for preparing parenterally administrable compositions are well known or will be apparent to those skilled in the art and are described in more detail in, for example, Remington&#39;s Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa. For the preparation of intravenously administrable antigen binding construct formulations of the invention see Lasmar U and Parkins D “The formulation of Biopharmaceutical products”, Pharma. Sci. Tech. today, page 129-137, Vol. 3 (3 Apr. 2000), Wang, W “Instability, stabilisation and formulation of liquid protein pharmaceuticals”, Int. J. Pharm 185 (1999) 129-188, Stability of Protein Pharmaceuticals Part A and B ed Ahern T. J., Manning M. C., New York, N.Y.: Plenum Press (1992), Akers, M. J. “Excipient-Drug interactions in Parenteral Formulations”, J. Pharm Sci 91 (2002) 2283-2300, Imamura, K et al “Effects of types of sugar on stabilization of Protein in the dried state”, J Pharm Sci 92 (2003) 266-274, Izutsu, Kkojima, S. “Excipient crystallinity and its protein-structure-stabilizing effect during freeze-drying”, J. Pharm. Pharmacol, 54 (2002) 1033-1039, Johnson, R, “Mannitol-sucrose mixtures-versatile formulations for protein lyophilization”, J. Pharm. Sci, 91 (2002) 914-922. 
     Preferably, the antigen binding protein of the invention is provided or administered at a dose of about 40 mg. Preferably the antigen binding protein is suitable for subcutaneous delivery and is delivered subcutaneously. Other dosing or administration routes may also be used, as disclosed herein. 
     In one emboduiment the antigen binding proteins according to any aspect of the invention shows increased Mean Residence Time as compared to an IgG comprising the light chain sequence of SEQ ID No. 2 and heavy chain sequence of SEQ ID No.12. 
     The binding ability of modified IgGs and molecules comprising an IgG constant domain or FcRn binding portion thereof can be characterized by various in vitro assays. PCT publication WO 97/34631 by Ward discloses various methods in detail. For example, in order to compare the ability of the modified IgG or fragments thereof to bind to FcRn with that of the wild type IgG, the modified IgG or fragments thereof and the wild type IgG can be radio-labeled and reacted with FcRn-expressing cells in vitro. The radioactivity of the cell-bound fractions can be then counted and compared. The cells expressing FcRn to be used for this assay are may be endothelial cell lines including mouse pulmonary capillary endothelial cells (B10, D2.PCE) derived from lungs of B10.DBA/2 mice and SV40 transformed endothelial cells (SVEC) (Kim et al., J Immunol., 40: 457-465, 1994) derived from C3H/HeJ mice. However, other types of cells which express sufficient number of FcRn, including mammalian cells which express recombinant FcRn of a species of choice, can be also used. Alternatively, after counting the radioactivity of the bound fraction of modified IgG or that of unmodified IgG, the bound molecules can be then extracted with the detergent, and the percent release per unit number of cells can be calculated and compared. 
     Affinity of antigen binding proteins of the inventions for FcRn can be measured by surface plasmon resonance (SPR) measurement using, for example, a BIAcore 2000 (BIAcore Inc.) as described previously (Popov et al., Mol. Immunol., 33: 493-502, 1996; Karlsson et al., J. Immunol. Methods, 145: 229-240, 1991, both of which are incorporated by reference in their entireties). In this method, FcRn molecules are coupled to a BIAcore sensor chip (e.g., CM5 chip by Pharmacia) and the binding of modified IgG to the immobilized FcRn is measured at a certain flow rate to obtain sensorgrams using BIA evaluation 2.1 software, based on which on- and off-rates of the modified IgG, constant domains, or fragments thereof, to FcRn can be calculated. Relative affinities of antigen binding proteins of the invention and unmodified IgG for FcRn can be also measured by a simple competition binding assay. Furthermore, affinities of modified IgGs or fragments thereof, and the wild type IgG for FcRn can be also measured by a saturation study and the Scatchard analysis. 
     Transfer of modified IgG or fragments thereof across the cell by FcRn can be measured by in vitro transfer assay using radiolabeled IgG or fragments thereof and FcRn-expressing cells and comparing the radioactivity of the one side of the cell monolayer with that of the other side. Alternatively, such transfer can be measured in vivo by feeding 10- to 14-day old suckling mice with radiolabeled, modified IgG and periodically counting the radioactivity in blood samples which indicates the transfer of the IgG through the intestine to the circulation (or any other target tissue, e.g., the lungs). To test the dose-dependent inhibition of the IgG transfer through the gut, a mixture of radiolabeled and unlabeled IgG at certain ratio is given to the mice and the radioactivity of the plasma can be periodically measured (Kim et al., Eur. R Immunol., 24: 2429-2434, 1994). 
     The half-life of antigen binding proteins can be measured by pharmacokinetic studies according to the method described by Kim et al. (Eur. J. of Immuno. 24: 542, 1994), which is incorporated by reference herein in its entirety. According to this method, radiolabeled antigen binding protein is injected intravenously into mice and its plasma concentration is periodically measured as a function of time, for example, at 3 minutes to 72 hours after the injection. The clearance curve thus obtained should be biphasic. For the determination of the in vivo half-life of the modified IgGs or fragments thereof, the clearance rate in β-phase is calculated and compared with that of the unmodified IgG. 
     Antigen binding proteins of the invention may be assayed for the ability to immunospecifically bind to an antigen. Such an assay may be performed in solution (e.g., Houghten, BiolTechniques, 13: 412-421, 1992), on beads (Lam, Nature, 354: 82-84, 1991, on chips (Fodor, Nature, 364: 555-556, 1993), on bacteria (U.S. Pat. No. 5,223,409), on spores (U.S. Pat. Nos. 5,571,698; 5,403,484; and 5,223,409), on plasmids (Cull et al., Proc. Natl. Acad. Sci. USA, 89: 1865-1869, 1992) or on phage (Scott and Smith, Science, 249: 386-390, 1990; Devlin, Science, 249: 404-406, 1990; Cwirla et al., Proc. Natl. Acad. Sci. USA, 87: 6378-6382, 1990; and Felici, J: Mol. Biol., 222: 301-310, 1991) (each of these references is incorporated herein in its entirety by reference). Antibodies that have been identified to immunospecifically bind to an antigen or a fragment thereof can then be assayed for their specificity affinity for the antigen. 
     The antigen binding proteins of the invention may be assayed for immunospecific binding to an antigen and cross-reactivity with other antigens by any method known in the art. Immunoassays which can be used to analyze immunospecific binding and cross-reactivity include, but are not limited to, competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), “sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley &amp; Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation). 
     In a preferred embodiment, BIAcore kinetic analysis is used to determine the binding on and off rates of antibodies to an antigen. BIAcore kinetic analysis comprises analyzing the binding and dissociation of an antigen from chips with immobilized antibodies on their surface. 
     Antigen binding protein: The term “antigen binding protein” as used herein includes reference to antibodies, antibody fragments and other protein constructs, which are capable of binding to TNF-alpha. 
     Antibody: The term “antibody” is used herein in the broadest sense and includes reference to molecules with an immunoglobulin-like domain and includes monoclonal, recombinant, polyclonal, chimeric, humanised, bispecific and heteroconjugate antibodies. 
     Human IgG1 heavy chain constant domain: refers to human amino acid sequence for the IgG1 heavy chain constant domain that is found in nature, including allelic variations. 
     “Half-life (t½)” refers to the time required for the concentration of the antigen binding polypeptide to reach half of its original value. The serum half-life of proteins can be measured by pharmacokinetic studies according to the method described by Kim et al. (Eur. J. of Immuno. 24: 542, 1994). According to this method, radiolabeled protein is injected intravenously into mice and its plasma concentration is periodically measured as a function of time, for example, at about 3 minutes to about 72 hours after the injection. Other methods for pharmacokinetic analysis and determination of the half-life of a molecule will be familiar to those skilled in the art. Details may be found in Kenneth, A et al: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and in Peters et al, Pharmacokinetic analysis: A Practical Approach (1996). Reference is also made to “Pharmacokinetics”, M Gibaldi &amp; D Perron, published by Marcel Dekker, 2nd Rev. ex edition (1982), which describes pharmacokinetic parameters such as t alpha and t beta half lives and area under the curve (AUC), and “Clinical Pharmacokinetics: Concepts and Applications”, Rowland and Tozer, Third Edition (1995). 
     “Clearance (CL)” refers to the volume of plasma irreversibly cleared of a protein per unit time. Clearance is calculated as the Dose/AUC (AUC: is the Area Under Curve or Area under the plasma drug concentration time curve). Clearance can also be calculated by the rate of drug elimination divided by the plasma concentration of the drug (rate of elimination=CL*concentration) 
     “Mean Residence Time (MRT)” is the average time that the antigen binding polypeptides reside in the body before being irreversibly eliminated. Calculated as MRT=AUMC/AUC. 
     “Steady state concentration” (Css) is the concentration reached when the drug elimination rate becomes equal to drug administration rate as a result of continued drug administration. Css fluctuates between peak and trough levels and is measured in microgram/ml. “Mean steady-state trough concentration” refers to the mean of the trough level across the patient population at a given time. 
     “Comparable mean steady-state trough concentration” refers to mean steady-state trough concentration which is the same or within about 10% to 30% of the stated value. Comparable mean steady-state trough concentration for the antigen binding polypeptides of the invention may be considered to be those mean steady-state trough concentrations that are 0.8 to 1.25 times the mean steady-state trough concentration achieved with an IgG comprising the light chain sequence of SEQ ID No. 2 and the heavy chain sequence of SEQ ID No. 12. 
     Half lives and AUC can be determined from a curve of serum concentration of drug (for example the antigen binding polypeptide of the present invention) against time. Half life may be determined through compartmental or non-compartmental analysis. The WINNONLIN™ analysis package (available from Pharsight Corp., Mountain View, Calif. 94040, USA) can be used, for example, to model the curve. In one embodiment, “half life” refers to the terminal half life. 
     Specifically binds: The term “specifically binds” as used throughout the present specification in relation to antigen binding proteins means that the antigen binding protein binds to TNF-alpha with no or insignificant binding to other unrelated proteins. The term however does not exclude the fact that the antigen binding proteins may also be cross-reactive with closely related molecules. The antigen binding proteins described herein may bind to TNF-alpha with at least 2, at least 5, at least 10, at least 50, at least 100, or at least 1000 fold greater affinity than they bind to closely related molecules. 
     CDRs: 
     “CDRs” are defined as the complementarity determining region amino acid sequences of an antigen binding protein. These are the hypervariable regions of immunoglobulin heavy and light chains. There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, “CDRs” as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy and light chain CDRs, or at least two CDRs. 
     Throughout this specification, amino acid residues in variable domain sequences and full length antibody sequences are numbered according to the Kabat numbering convention. Similarly, the terms “CDR”, “CDRL1”, “CDRL2”, “CDRL3”, “CDRH1”, “CDRH2”, “CDRH3” used in the Examples follow the Kabat numbering convention. For further information, see Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987). 
     % identity of variants: The term “identical” or “sequence identity” indicates the degree of identity between two nucleic acid or two amino acid sequences when optimally aligned and compared with appropriate insertions or deletions. The variants described herein may have 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to the native CDR or variable domain sequences at the amino acid level. 
     It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine study, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects. 
     As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. In one aspect such open ended terms also comprise within their scope a restricted or closed definition, for example such as “consisting essentially of”, or “consisting of”. 
     The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context. 
     All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. 
     All documents referred to herein are incorporated by reference to the fullest extent permissible. 
     Any element of a disclosure is explicitly contemplated in combination with any other element of a disclosure, unless otherwise apparent from the context of the application. 
     The present invention is further described by reference to the following examples, not limiting upon the present invention. 
     EXAMPLES 
     Example 1 
     Cloning of Antibody Expression Vectors 
     The DNA expression constructs encoding the variable heavy (VH) and variable light (VL) domains of an anti-TNFα antibody were previously prepared de novo and included restriction sites for cloning into mammalian expression vectors. Both heavy and light chain variable domain sequences were sequence optimised for expression in mammalian cells (for methodology see WO2009024567 and Kotsopoulou et al,  J Biotechnol  (2010) 146: 186-193). Information describing the heavy and light chain variable region sequences can be found in U.S. Pat. No. 6,090,382. To generate the constructs used in this study, the variable heavy domain (VH) sequences were amplified using PCR. The PCR primers contained HindIII and SpeI restriction sites to frame the VH domain containing the signal sequence for cloning into a pTT mammalian expression vectors containing the human γ1 constant region. Similarly the VL domain sequence was amplified by PCR using primers containing HindIII and BsiWI restriction sites to facilitate cloning into a pTT mammalian expression vector containing the human kappa constant region. The heavy chain expression plasmid was given the code SJC322 and the light chain expression plasmid was given the plasmid code SJC321. 
     DNA expression constructs encoding alternative variable heavy and light chain regions of anti-TNFα antibodies with modifications in the CDR regions (as described in Rajpal et al. PNAS (2005) 102(24): pg 8466-8471) were prepared de novo by build up of overlapping oligonucleotides and similar molecular biology techniques to those described above. The resulting plasmids encoding the heavy and light chains of variants cb1-3, cb2-6 and cb2-44 are described in Table 1. 
     Example 2 
     Engineering of the Fc Region 
     Forward and reverse priming primers were used to introduce modifications (M252Y/S254T/T256E and T250Q/M428L) into the human γ1 constant region of the plasmid encoding the heavy chain of pascolizumab (anti-IL-4 antibody) using the Quikchange protocol (Promega). 
     As described in Example 1 above, a PCR fragment encoding the VH domain of an anti-TNFα antibody was generated using a previously constructed, codon optimised vector as a template. The resulting fragment was cloned using HindIII and SpeI into a pTT expression vector containing the modified human γ1 constant region described in the preceding paragraph. The plasmid encoding the heavy chain of the anti-TNFα antibody with the M252Y/S254T/T256E modification was designated SJC324. The plasmid encoding the heavy chain with the T250Q/M428L modification was designated SJC323. 
     Forward and reverse priming primers were used to introduce modifications into the human γ1 constant region of anti-TNFα heavy chain expression plasmid SJC322 using the Quikchange protocol (Promega). Plasmid SJC326 encodes the anti-TNFα heavy chain containing the M428L/N434S modification in the human γ1 constant region. Plasmid SJC328 encodes the anti-TNFα heavy chain containing the V308F modification in the human γ1 constant region. 
     Example 3 
     Expression of Antibodies in HEK2936E Cells Using pTT5 Episomal Vectors 
     Expression plasmids encoding the heavy and light chains described above were transiently co-transfected into HEK 293 6E cells. Expressed antibody was purified from the supernatant by affinity chromatography using a 1 ml HiTrap Protein A column (GE Healthcare). Table 1 below shows the list of antibodies produced. 
     Some antibodies were also expressed in CHO cells using a different set of expression vectors. See Examples 13, 14 and 15 for a description of the molecular biology, expression and purification. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 List of expressed antibodies 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 Heavy 
                 SEQ 
                 Light 
                 SEQ 
               
               
                   
                   
                   
                 chain 
                 ID of 
                 chain 
                 ID of 
               
               
                   
                   
                   
                 expression 
                 heavy 
                 expression 
                 light 
               
               
                 BPC code 
                 CDR variant 
                 Fc modifications 
                 vector 
                 chain 
                 vector 
                 chain 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 BPC1492 
                 None 
                 Wild-type 
                 SJC322 
                 12 
                 SJC321 
                 2 
               
               
                 BPC1494 
                 None 
                 M252Y/S254T/T256E 
                 SJC324 
                 5 
                 SJC321 
                 2 
               
               
                 BPC1496 
                 None 
                 M428L/N434S 
                 SJC326 
                 9 
                 SJC321 
                 2 
               
               
                 BPC1493 
                 None 
                 T250Q/M428L 
                 SJC323 
                 15 
                 SJC321 
                 2 
               
               
                 BPC1498 
                 None 
                 V308F 
                 SJC328 
                 18 
                 SJC321 
                 2 
               
               
                 BPC1499 
                 cb1-3 
                 Wild-type 
                 SJC336 
                 150 
                 SJC339 
                 147 
               
               
                 BPC1500 
                 cb2-44 
                 Wild-type 
                 SJC337 
                 151 
                 SJC340 
                 148 
               
               
                 BPC1501 
                 cb2-6 
                 Wild-type 
                 SJC336 
                 150 
                 SJC338 
                 149 
               
               
                   
               
            
           
         
       
     
     Example 4 
     Binding of Antibodies to Tumour Necrosis Factor Alpha in a Direct Binding ELISA 
     A binding ELISA was carried out to test the binding of the expressed antibodies purified using protein A to recombinant tumour necrosis factor alpha (TNFα). ELISA plates were coated with recombinant human TNFα at 0.1 μg/ml and blocked with blocking solution (4% BSA. Various dilutions of the purified antibody were added (diluted in 4% BSA in T Tris-buffered saline at pH8.0 containing 0.05% Tween 20) and the plate was incubated for 1 hour at room temperature before washing in deionised water. Binding was detected by the addition of a peroxidase labelled anti human kappa light chain antibody (Sigma A7164) in blocking solution. The plate was incubated for 1 hour at room temperature before washing in deionised water. The plate was developed by addition of OPD substrate (Sigma P9187) and colour development stopped by addition of 2M HCl. Absorbance was measured at 490 nm with a plate reader and the mean absorbance plotted against concentration. The results are shown in  FIG. 1  and confirm that all the antibodies have a similar profile. 
     Example 5 
     Analysis of Antibodies in an L929 In Vitro Neutralisation Assay 
     This assay was used to test the neutralising ability of the antibodies to neutralise TNF-α and inhibit cell death. Briefly, L929 cells were seeded in a 96-well flat-bottomed plate at 10,000/well in 100 μl RPMI 1640 (w/o phenol red) and incubated overnight at 37° C., 5% CO 2 . Cells were sensitised with 1.25 μg/ml actinomycin D for 1 hour. For the neutralising study, 0.001-60 μg/ml (0.0067-400 nM) anti-TNF-α mAb was pre-incubated with approx. 2 ng/ml (approximately 0.05 nM) TNF-α in a 1:1 ratio for 1 hour at room temperature. For control group, RPMI was used in place of the antibody. Following the 1 h pre-incubation with actinomycin D, 20 μl of antibody-antigen complex was added per well. 10 μl media alone was added to wells as a negative control. Plates were incubated at 18 hour at 37° C., 5% CO 2 . Following this treatment period, cell viability was determined by a cell titer-Glo Luminescent assay kit according to manufacturer&#39;s instructions (Promega, Madison USA). For L929 assay, the percentage cell viability of the unknowns was expressed as a percentage of the untreated group (taken as a 100%) and IC50 values were determined by Graphpad prism. Differences in IC50 values of antibodies was assessed by one-way ANOVA (Newman-Keuls post hoc test) and considered significant at P-values of less than 0.05. Data is represented as mean±SEM, of n=4 experiments measured in duplicate. IC50 values for each antibody were determined and are listed in Table 2 below. The results show that the potency of all the antibodies tested are comparable. 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 IC 50  values for various anti-TNFα 
               
               
                 antibodies in an L929 neutralisation assay 
               
            
           
           
               
               
               
            
               
                   
                 Antibody 
                 IC 50  value (μg/ml) 
               
               
                   
                   
               
               
                   
                 BPC1492 
                 1.19 ± 0.10 
               
               
                   
                 BPC1494 
                 1.20 ± 0.13 
               
               
                   
                 BPC1496 
                 1.18 ± 0.10 
               
               
                   
                 Adalimumab 
                 1.09 ± 0.07 
               
               
                   
                   
               
            
           
         
       
     
     Table 3 shows the IC50 values derived from the experiment. The results indicate that the improved anti-TNFα antibodies (BPC1499, BPC1500, BPC1501) show increased potency in this assay compared to BPC1492 and adalimumab. 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 IC 50  values for improved anti-TNFα 
               
               
                 antibodies in an L929 neutralisation assay 
               
            
           
           
               
               
               
            
               
                   
                 Antibody 
                 IC 50  value (μg/ml) 
               
               
                   
                   
               
               
                   
                 BPC1492 
                 1.19 ± 0.1  
               
               
                   
                 BPC1499 
                 0.21 ± 0.04 
               
               
                   
                 BPC1500 
                 0.13 ± 0.02 
               
               
                   
                 BPC1501 
                 0.21 ± 0.03 
               
               
                   
                 Adalimumab 
                 1.09 ± 0.07 
               
               
                   
                   
               
            
           
         
       
     
     Example 6 
     Effect of Antibodies on In Vitro IL-6 Release 
     The neutralising ability of antibodies was determined by measuring their effect on inhibiting TNF-α mediated IL-6 release from whole blood cells. Briefly, 130 μL of whole blood was added to each well and plates were incubated at 37° C. in a humidified 5% CO 2  incubator for 1 hour. For the neutralising study, 0.001-30 μg/ml (0.0067-200 nM) TNF-α mAb was pre-incubated with 10 ng/ml (approx. 0.4 nM) TNF-alpha in a 1:1 ratio for 1 hour at 4° C. For control group, RPMI was used in place of the antibody. Following this pre-treatment, 20 μl of antigen-antibody complex or RPMI (negative control) was added per well and plates were incubated for 24 hour at 37° C., 5% CO 2 . 100 μL PBS (w/o MgCl 2  or CaCl 2 ) added to each well and placed on plate shaker for 10 mins at 500 rpm. Plates were then spun at 2000 rpm for 5 mins. 120 μL supernatant was carefully removed and transferred to fresh 96-well round bottomed plate and IL-6 release was determined using an MSD based assay kit (Meso Scale Diagnostics, Maryland USA). For the whole blood assay, the MSD signal for each sample was read using a MSD SECTOR® Imager 2400 and IL-6 release from the cells was quantified using a standard data analysis package in PRISM 4.00 software (GraphPad. San Diego, USA). The percentage of IL-6 inhibition by each antibody was expressed as a percentage of the TNF-α alone treated group. Hence, dose response curves were obtained for each antibody and IC50 values were determined. Using the log of the IC50 values, the difference in potency of the antibodies was determined by one-way ANOVA (Newman-Keuls post hoc test) and considered significant at P-values of less than 0.05 for each donor (n=3). Data is represented as mean±SEM of three donors, measured in duplicate. Table 4 below shows the IC50 values derived from these data. These results suggest that there is no significant difference in potency between the antibodies tested. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 IC 50  values for various anti-TNF antibodies 
               
               
                 in a TNFα-induced IL-6 release assay 
               
            
           
           
               
               
               
            
               
                   
                 Antibody 
                 IC 50  value (nM) 
               
               
                   
                   
               
               
                   
                 BPC1492 
                 0.72 ± 0.32 
               
               
                   
                 BPC1494 
                 0.62 ± 0.11 
               
               
                   
                 BPC1496 
                 0.64 ± 0.13 
               
               
                   
                 Adalimumab 
                 0.47 ± 0.09 
               
               
                   
                   
               
            
           
         
       
     
     The IC50 values are shown in Table 5. The results indicate that the improved anti-TNFα antibodies (BPC1499, BPC1500, BPC1501) show increased potency in this assay. 
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 IC 50  values for various improved anti-TNF antibodies 
               
               
                 in a TNFα-induced IL-6 release assay 
               
            
           
           
               
               
               
            
               
                   
                 Antibody 
                 IC 50  value (nM) 
               
               
                   
                   
               
               
                   
                 BPC1492 
                 0.72 ± 0.32 
               
               
                   
                 BPC1494 
                 0.62 ± 0.12 
               
               
                   
                 BPC1499 
                 0.14 ± 0.02 
               
               
                   
                 BPC1500 
                 0.11 ± 0.05 
               
               
                   
                 BPC1501 
                 0.15 ± 0.03 
               
               
                   
                 Adalimumab 
                 0.47 ± 0.09 
               
               
                   
                   
               
            
           
         
       
     
     Example 7 
     Accelerated Stressor Studies 
     Prior to the study, antibodies to be tested were quantified on a spectrophotometer at OD280 nm and diluted to 1.1 mg ml in PBS (pH7.4). An aliquot was removed and 10% v/v of 500 mM sodium acetate was added to give a final concentration of 1 mg/ml at pH5.5 and the sample inspected for precipitation. The remaining sample in PBS had 10% PBS v/v added to a final concentration of 1 mg/ml at pH7.4 and an aliquot of this sample was removed to provide a baseline aggregation level (as monitored by size exclusion chromatography). The samples were then incubated at 37° C. for two weeks in an incubator, after which the samples were re-quantified on a spectrophotometer at OD280 nm and assessed (by size exclusion chromatography) for aggregation. The samples were tested for human TNFα binding in a direct binding ELISA. The results are shown in  FIG. 2  and confirm that the binding activity of all antibodies tested is comparable following the accelerated stressor study. 
     Example 8 
     Stability Study in 25% Human Serum 
     Prior to the study, antibodies to be tested were quantified on a spectrophotometer at OD280 nm and diluted to 1.25 mg/ml in PBS (pH7.4). An aliquot was removed and 25% v/v of human serum was added to give a final concentration of 1 mg/ml. The remaining sample in PBS had 25% PBS v/v added to a final concentration of 1 mg/ml and an aliquot of this sample was removed to provide a baseline level. The samples were then incubated at 37° C. for two weeks in an incubator, after which the samples were tested for human TNFα binding in a direct binding ELISA. The results are shown in  FIG. 3  and confirm that the binding activity of all antibodies tested is comparable following incubation in 25% human serum for two weeks. 
     Example 9 
     Analysis of Binding to Human TNFα Following Freeze-Thaw 
     Antibody samples were diluted to 1 mg/ml in a buffer containing 50 mM Acetate and 150 mM NaCl (pH6.0), snap-frozen in dry ice and then thawed at 4° C. overnight. Binding of the antibodies to human TNFα was tested in comparison to an antibody which had not been snap-frozen. To assess the binding activity following freeze-thaw, ELISA plates were coated with recombinant human TNFα at 1 μg/ml and blocked with blocking solution (4% BSA in Tris buffered saline). Various concentrations were added to the coated plates and incubated for 1 hour at room temperature before washing in deionised water. Binding was detected by the addition of a peroxidase labelled anti human kappa light chain antibody (Sigma A7164) in blocking solution. The plate was incubated for 1 hour at room temperature before washing in deionised water. The plate was developed by addition of OPD substrate (Sigma P9187) and colour development stopped by addition of 2M HCL. Absorbance was measured at 490 nm with a plate reader and the mean absorbance plotted against concentration. The results are shown in  FIG. 4  and confirm that the binding activity of all antibodies tested is comparable following freeze-thaw. 
     Example 10 
     Analysis of Binding of Anti-TNFα Antibodies to FcγRIIIa 
     ELISA plates were coated with recombinant human FcγRIIIa (V158 and F158 variants) at 1 μg/ml and blocked with blocking solution (4% BSA in Tris buffered saline). Various concentrations were added to the coated plates and incubated for 1 hour at room temperature before washing in deionised water. Binding was detected by the addition of a peroxidase labelled anti human kappa light chain antibody (Sigma A7164) in blocking solution. The plate was incubated for 1 hour at room temperature before washing in deionised water. The plate was developed by addition of OPD substrate (Sigma P9187) and colour development stopped by addition of 2M HCl. Absorbance was measured at 490 nm with a plate reader and the mean absorbance plotted against concentration. The results are shown in  FIGS. 5   a  and  5   b  and confirms that BPC1494 has reduced capacity to bind FcγRIIIa (V158 and F158 variants) compared to BPC1492 and BPC1496. 
     Example 11 
     PreteOn Analysis: FcRn Binding 
     Antibodies for testing were immobilised to similar levels on a GLC biosensor chip (BioRad 176-5011) by primary amine coupling. Recombinant human and cynomolgus FcRn were used as analytes at 2048 nM, 512 nM, 128 nM, 32 nM, and 8 nM, an injection of buffer alone (i.e. 0 nM) was used to double reference the binding curves. Regeneration of the antibody surface following FcRn injection used HBS-N at pH9.0, the assay was run on the PrateOn XPR36 Protein Interaction Array System at 25° C. and run in HBS-N pH7.4 and HBS-N pH6.0 with the FcRn diluted in appropriate buffer. Affinities were calculated using Equilibrium model, inherent to the PrateOn analysis software, using a “Global R-max” for binding at pH6.0 and the R-max from binding at pH6.0 for affinity calculation at pH7.4. Since the binding curves did not reach saturation at pH7.4, the values obtained are unlikely to be true affinities however they can be used to rank constructs. The results are shown in Table 6 and confirm that BPC1494 and BPC1496 have an improved affinity for human and cyno FcRn at pH6.0 when compared to BPC1492. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Affinities of Anti-TNF alpha constructs 
               
               
                 binding to Human and Cyno FcRn 
               
            
           
           
               
               
               
               
               
            
               
                 BPC 
                 Human pH 6.0 
                 Human pH 7.4 
                 Cyno pH 6.0 
                 Cyno pH 7.4 
               
               
                 Number 
                 KD(nM) 
                 KD(nM) 
                 KD(nM) 
                 KD(nM) 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 BPC1492 
                 554 
                 21200 
                 579 
                 29700 
               
               
                 BPC1494 
                 204 
                 2320 
                 239 
                 2640 
               
               
                 BPC1496 
                 144 
                 1910 
                 154 
                 2100 
               
               
                 BPC1497 
                 428 
                 15500 
                 464 
                 20800 
               
               
                 BPC1498 
                 357 
                 5910 
                 402 
                 6280 
               
               
                 BPC1493 
                 264 
                 4390 
                 295 
                 4690 
               
               
                   
               
            
           
         
       
     
     Example 12 
     PK Studies in Human FcRn Transgenic Mice 
     In a single dose pharmacokinetic study BPC1494 and BPC1492, were administered intravenously (IV) at 1 mg/kg to two different strains of FcRn humanised mice and one strain deficient in FcRn (Petkova et al.  Int. Immunol  (2010) 18(12): 1759-1769). Plasma samples were analyzed for BPC1494 or BPC1492, as appropriate, using a validated Gyrolab fluorescent immunoassay. 
     The methods used biotinylated human TNF alpha as the capture antigen and an Alexa labelled anti-human IgG (Fc specific) antibody as the detection antibody. Using an aliquot of mouse plasma diluted 1:10 with assay buffer, the lower limit of quantification (LLQ) was 100 ng/mL and the higher limit of quantification (HLQ) was 100,000 ng/mL. Plasma concentrations below the lowest standards were considered to be not quantifiable. QC samples prepared at three different concentrations and stored with the study samples, were analysed with each batch of samples against separately prepared calibration standards. For the analyses to be acceptable, at least one QC at each concentration must not deviate from nominal concentration by more than 20%. The QC results from this study met these acceptance criteria. 
     PK analysis was performed by non-compartmental pharmacokinetic analysis using WinNonLin, version 6.1. All computations utilised the nominal blood sampling times. The systemic exposure to BPC1494 and BPC1492 was determined by calculating the area under the plasma concentration time curve (AUC) from the start of dosing until the last quantifiable time point (AUC 0-t ) using the linear log trapezoidal calculation method. Further PK parameters could not be derived from the data due discrepancies in sample labelling. 
     
       
         
           
               
             
               
                 TABLE 7 
               
             
            
               
                   
               
               
                 Summary pharmacokinetic parameters for BPC1494 and BPC1492 
               
               
                 following a single intravenous administration (bolus) 
               
               
                 at a target dose of 1 mg/kg to transgenic mice 
               
            
           
           
               
               
               
               
               
            
               
                   
                 Compound 
                 Strain 
                 Cmax (ug/mL) 
                 AUC (hr*ug/mL) 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 BPC1494 
                 1 
                 13.8 
                 2240 
               
               
                   
                 BPC1492 
                   
                 14.8 
                 1730 
               
               
                   
                 BPC1494 
                 2 
                 12.0 
                 1320 
               
               
                   
                 BPC1492 
                   
                 13.2 
                 1060 
               
               
                   
                 BPC1494 
                 3 
                 13.6 
                 214 
               
               
                   
                 BPC1492 
                   
                 12.2 
                 250 
               
               
                   
                   
               
               
                   
                 Strain 1 = mFcRn−/− hFcRn (32) Tg/Tg 
               
               
                   
                 Strain 2 = mFcRn−/− hFcRn (276) Tg/Tg Rag1−/− 
               
               
                   
                 Strain 3 = mFcRn −/−/Rag1−/− 
               
               
                   
                 Similar C max  concentrations were obtained for all groups. In both human FcRn knock-in mouse strains BPC1494 had a higher exposure (AUC 0-t ) than BPC1492, although this difference was not notable (1.3 fold). In the absence of both human and mouse FcRn BPC1492 had a higher exposure than BPC1494. 
               
            
           
         
       
     
     Example 13 
     Cloning of Antibody Expression Vectors into pEF Vectors 
     In some cases, the DNA encoding the expression cassettes for the heavy and light chains were excised from the vectors described in Example 3 using HindIII and EcoRI and cloned into pEF vectors, where expression occurs from the hEF1a promoter, using standard molecular biology techniques (for description of vectors see Kotsopoulou et al  J. Biotechnol  (2010) 146: 186-193). 
     
       
         
           
               
               
               
               
               
               
             
               
                 TABLE 8 
               
               
                   
               
               
                   
                   
                 Heavy 
                 Light 
                 Heavy 
                 Light 
               
               
                   
                   
                 chain 
                 chain 
                 chain 
                 chain 
               
               
                 BPC 
                 Fc 
                 expression 
                 expression 
                 SEQ 
                 SED 
               
               
                 code 
                 modification 
                 vectors 
                 vector 
                 ID No. 
                 ID No. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 BPC1492 
                 None 
                 SJC330 
                 SJC329 
                 12 
                 2 
               
               
                 BPC1494 
                 M252Y/S254T/ 
                 SJC331 
                 SJC329 
                 5 
                 2 
               
               
                   
                 T256E 
               
               
                 BPC1496 
                 M428L/N434S 
                 SJC332 
                 SJC329 
                 9 
                 2 
               
               
                   
               
            
           
         
       
     
     Example 14 
     Expression of Antibodies in CHO Cells Using pEF Expression Vectors 
     Expression plasmids encoding heavy and light chains were co-transfected into CHO DG44 cells and expressed at scale to produce antibody. For the generation of BPC1492 plasmids SJC329 and SJC330 were used. For the expression of BPC1494 plasmids SJC329 and SJC331 were used. For BPC1496 plasmids SJC329 and SJC332 were used. 
     Briefly, 30 μg DNA (15 μg heavy chain and 15 μg light chain) was linearised overnight with Not1 restriction enzyme. The resultant restricted DNA was then ethanol precipitated and re-dissolved in TE buffer. From culture, 6×10 6  CHO DG44 cells were obtained and washed in 10 ml of PBS. The cell pellet was then re-suspended in 300 μl of Amaxa solution V. 100 μl of the aforementioned cell suspension was then added into to each of three Amaxa cuvettes, which also contained 3 μg of the linearised DNA. The cuvettes were inserted into an Amaxa nucleofector II device and electroporated with pre-set programme U-023. The contents of the three cuvettes (300 μl) of electroporated cells were added to 10 ml of warmed MR14 medium (including nucleosides and BSA) and incubated in a T75 flask for 48 hours. Following this period, the medium was changed to nucleoside-free-MR14 (MR14 containing only BSA)). Every 3-4 days, conditioned medium was removed and replaced with fresh selection medium. Once cells had undergone recovery, the medium was substituted to 2×MR14 and IgG expression was confirmed by nephlometry. 2 L shake-flasks were seeded with 1 L of the IgG-expressing cells at 0.6×10 6 /ml and grown for 7 days. Cells were separated from supernatant by centrifugation and the supernatant was used for protein purification. 
     1 litre cell culture supernatants were purified using a 2-step automated process on an AKTA Xpress system. The antibody was captured on a 5 ml MabSelectSure column and then washed prior to elution. The eluted antibody was then loaded onto a 440 ml Superdex 200 gel filtration column and 2 ml fractions collected in a 96-well block. Fractions of purified antibody were pooled and 0.2 μm filtered and then concentrated to ˜5 mg/ml using Amicon spin concentrators. The final material was again 0.2 μm filtered and then dispensed into sterile tubes for delivery. The final material was subject to analytical SEC to determine aggregation, an endotoxin assay, LC-MS for accurate mass determination (included PNGaseF and untreated material to determine glycosylation), SDS PAGE electrophoresis, PMF for sequence confirmation and A280 for concentration determination. 
     Example 15 
     Alternative Method for Expression of Antibodies in CHO Cells Using pEF Expression Vectors 
     DHFR-null CHO DG44 cells were obtained from Dr. Chasin of Columbia University. These cells were subsequently adapted to a chemically defined medium. These adapted host cells were designated DG44-c and are cultured in proprietary chemically defined medium supplemented with Glutamax and HT-supplement. 
     Generation of the polyclonal pool: For more details on protocols see WO2009024567 and Kotsopoulou et al, J. Biotechnol (2010) 164(4): 186-193. Briefly, DG44-c cells were transfected with plasmids encoding the heavy and light chains and DHFR and neoR respectively by electroporation (using the Amaxa nucleofector system). At 48 hours post transfection, selection was initiated by addition of G418 (at a final concentration of 400 μg/ml) and removal of HT. When viability and cell counts increased sufficiently (in this case 2 months post transfection) methotrexate (MTX) was added at a final concentration of 5 nM. Cells were scaled up and production curves were initiated 9-16 days after addition of MTX. For these production curves cells were seeded at 0.6-0.8×10 6  cells/ml in chemically defined media and were fed on days 6, 9 or 10, 12 or 13 and/or 16. Supernatant was collected when viability dropped to approximately 50% and the cells were removed by centrifugation at 4000 g for 30 mins followed by filtration through a sartobran capsule. 
     Antibodies were purified at room temperature using a two step chromatographic procedure: Initial capture was performed using a 50 ml MabSelect SuRe column (GE Healthcare) followed by Size Exclusion Chromatography (SEC) with a 1.5 L Superdex 200 μg SEC (GE Healthcare). The conditioned media was loaded onto a pre-equilibrated MabSelect SuRe column at a flow rate of 9 cm/h. Following washing to base line with equilibration buffer (50 mm Tris pH 8.0, 2M NaCl) the column was washed with a low salt buffer buffer (50 mM NaCl Tris pH 8.0, 150 mM NaCl) until conductivity was stable. The column was then eluted with elution buffer (25 mM Citrate pH 2.5). Fractions corresponding to peak protein elution were immediately neutralized with 1/10 vol. 1.0M Tris pH 8.0 which were then pooled and filtered through a 0.2 μm bottletop filter. The recovered sample was loaded at 21 cm/h onto the SEC column pre-equilibrated with SEC buffer (50 mM Na Acetate, 150 mM NaCl). The fractions containing the main (monomeric) protein peak were pooled and filter sterilized. 
     Antibodies prepared by this method were used for analytical comparability studies summarised in the following example. 
     Examples 16 
     Analytical Comparability on Stressed and Control Samples 
     Size exclusion chromatography was carried out to determine the aggregation levels of the protein. The optimised method involved injection of the sample onto a TOSOH TSK G3000SWXL column which had been equilibrated in 100 mM sodium phosphate, 400 mM NaCl, pH 6.8. Absorbance was measured at both 280 nm and 214 nm. Reverse-phase HPLC separates proteins and their isoforms based on hydrophobicity. Protein was injected onto a PLRP-S 1000° A 8 μm column and eluted using a gradient produced by 50% Formic acid, and 95% Acetonitrile. Absorbance was measured at 280 nm. The purity of the molecule is reported as a percentage of the main peak area relative to the total peak area. Different isoforms of the mAb were separated on the basis of their pI values using capillary isoelectric focussing (cIEF). IEF separation was performed on a 10 cm, UV280 transparent cartridge capillary. The optimised method involved a solution containing 5% pH 3-10 ampholytes, 10 mM NaOH, protein of interest and internal pI markers (7.05 and 9.5) which was loaded into the capillary by pressure injection. 
     The specific activity of antibodies (adalimumab, BPC1494, BPC1496) was determined using MSD. In brief, 96-well plates were coated with 50 μL per well TNFα diluted to 1 μg/mL in PBS. The plate was incubated on the bench top at ambient temperature without shaking for 2 hours. The coating solution was removed and the plate was blocked with 50 μL per well of 1% BSA in PBS, with 0.05% Polysorbate 20. The plate was incubated for 1 hour at 24° C. with shaking at 400 rpm and then washed 4 times with wash buffer. The antibodies were diluted in 0.1% BSA in PBS with 0.05% Polysorbate 20 and 30 μl of each sample was added to the plate. The plate was incubated for 1 hour at 24° C. with shaking at 400 rpm. The plate was then washed 4 times with wash buffer. Anti-human IgG sulfotag was diluted 1 in 5000 in assay buffer. 30 μL was added to each well of the plate and then incubated for 1.5 hour at 24° C., with shaking at 400 rpm. The plate was then washed 4 times with wash buffer. The 4×MSD Read Buffer concentrate was diluted to 1× using deionised water. 100 μL was then added per well of the plate. The plate was then read using the MSD Sector Imager instrument. From the signals obtained from the assay, specific activities of the molecules were calculated. 
     Deamidation Analysis 
     Deamidation is a common post-translational modification that can occur to asparagine and glutamine residues, but is most commonly observed with asparagine residues, particularly when adjacent to a glycine residue. In order to examine how susceptible these residues are and to determine the effects of deamidation on potency, adalimumab, BPC1494 and BPC1496 were exposed to a stress study. The stress was carried out by incubation in 1% ammonium bicarbonate at pH 9.0, for 48 hrs, conditions which have previously been shown to cause deamidation. The stressed samples were incubated alongside a control (in PBS) and were compared to this as well as an unstressed reference and analysed using c-IEF, SEC and Binding ELISA. Forced deamidation was also done on all samples in the presence and absence of EDTA. It has been shown previously that forced deamidation conditions cause fragmentation in addition to deamidation. EDTA prevents and or minimizes the fragmentation. 
     Oxidation Analysis 
     Oxidation of various residues can occur throughout the processing and storage of proteins; however the most commonly oxidised residue is methionine, which was the focus of this screen. Oxidation susceptibility of these residues was examined through exposure to stress conditions by incubation in 5 mM and 50 mM H 2 O 2  for 30 minutes and evaluated using RP-HPLC, SEC and ELISA. 
     Summary of Results 
     Both BPC1494 and BPC1496 behave very favourably compared to adalimumab as shown by analytical comparability on both stressed and control samples. For all antibodies tested, no significant degradation was observed under forced oxidation conditions as shown by all analytical techniques employed. Significant deamidation as measured by c-IEF was observed at pH 9.0 as expected for all antibodies tested. In addition we saw significant fragmentation for all antibodies tested as shown by SEC at pH 9.0 in samples without EDTA, this is also as expected. There is a reduction in the pI value, (approximately 0.2) of BPC1494 when compared to adalimumab. This is attributed to the presence of an additional glutamic acid residue in the heavy chain sequence of the BPC1494 thus making it more acidic. Forced deamidation and oxidation had minimal impact on binding and this was observed for BPC1494, BPC1496 and adalimumab. 
     Example 17 
     Analysis of Binding of Improved Antibodies by ELISA 
     Antibodies BPC1499, 1500 and 1501 were assessed for binding activity by ELISA as described in Example 4. Using two different antigen coating concentrations (0.1 and 1.0 μg/ml), the antibodies did not show any difference in their binding profile when compared with BPC1492. Under the conditions tested, it appears that the ELISA does not discriminate between antibodies with different reported binding activities. The same antibodies were assessed using methodologies described in Examples 18, 5 and 6 which are considered more sensitive assays. In these assays, antibodies BPC1499, 1500 and 1501 show improved binding affinity and improved potency when compared with BPC1492. 
     Example 18 
     Biacore Analysis of TNF Alpha Binding Using a Capture Surface 
     Protein A and anti-human IgG (GE Healthcare BR-1008-39) were coupled on separate flow cells on a CM3 biosensor chip. These surfaces were used to capture the antibodies for binding analysis. Recombinant human and cynomolgus TNF alpha were used as analytes at 64 nM, 21.33 nM, 7.11 nM, 2.37 nM, 0.79 nM, an injection of buffer alone (i.e. 0 nM) used to double reference the binding curves. Regeneration of the capture surface was carried out using 100 mM phosphoric acid and 3M MgCl 2 . The run was carried out on the Biacore T100 machine at 37° C. using HBS-EP as running buffer. The constructs BPC1494 and BPC1496 showed reduced binding to Protein A and the anti-human IgG surface making these surfaces unsuitable for generating kinetics for those molecules. 
     
       
         
           
               
             
               
                 TABLE 9 
               
             
            
               
                   
               
               
                 Kinetic Analysis of Human and Cyno TNF alpha Binding 
               
               
                 to Captured Anti-TNF alpha Antibodies. 
               
            
           
           
               
               
               
               
               
               
            
               
                 Construct 
                 Analyte 
                 Capture Surface 
                 ka(1/Ms) 
                 kd(1/s) 
                 KD(nM) 
               
               
                   
               
               
                 BPC1492 
                 human TNFα 
                 Protein A 
                 2.12E+06 
                 1.10E−04 
                 0.05196 
               
               
                 BPC1494 
                 human TNFα 
                 Protein A 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1496 
                 human TNFα 
                 Protein A 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1500 
                 human TNFα 
                 Protein A 
                 2.68E+06 
                 4.19E−05 
                 0.01561 
               
               
                 BPC1492 
                 human TNFα 
                 anti-human IgG 
                 6.78E+06 
                 1.73E−04 
                 0.02554 
               
               
                 BPC1494 
                 human TNFα 
                 anti-human IgG 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1496 
                 human TNFα 
                 anti-human IgG 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1500 
                 human TNFα 
                 anti-human IgG 
                 4.51E+06 
                 7.07E−05 
                 0.01568 
               
               
                 BPC1492 
                 Cyno TNFα 
                 Protein A 
                 1.10E+06 
                 1.11E−04 
                 0.101  
               
               
                 BPC1494 
                 Cyno TNFα 
                 Protein A 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1496 
                 Cyno TNFα 
                 Protein A 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1500 
                 Cyno TNFα 
                 Protein A 
                 2.34E+06 
                 3.51E−05 
                 0.01503 
               
               
                 BPC1492 
                 Cyno TNFα 
                 anti-human IgG 
                 1.96E+06 
                 3.75E−04 
                 0.1911  
               
               
                 BPC1494 
                 Cyno TNFα 
                 anti-human IgG 
                 Data 
                 not 
                 Analysable 
               
               
                 BPC1496 
                 Cyno TNFα 
                 anti-human IgG 
                 Data 
                 not 
                 analysable 
               
               
                 BPC1500 
                 Cyno TNFα 
                 anti-human IgG 
                 4.48E+06 
                 2.09E−04 
                 0.04667 
               
               
                   
               
            
           
         
       
     
     Example 19 
     ProteOn Reverse Assay Binding Analysis 
     Biotinylated TNF alpha was mixed with biotinylated BSA at a 1:49 ratio, at a final total protein concentration of 20 μg/ml (i.e. 0.4 μg biotinylated TNF alpha and 19.6 μg biotinylated BSA). This mixture was captured on a NLC biosensor chip (a single flowcell) (Biorad 176-5021). The chip surface was conditioned with 10 mM glycine pH3.0 till a stable signal was achieved. The antibodies to be tested were used as analytes at 256 nM, 64 nM, 16 nM, 4 nM and 1 nM and 0 nM. The binding curves were referenced against a flowcell coated with biotinylated BSA alone. Regeneration was achieved using 10 mM glycine pH3.0. Data was fitted to the 1:1 model inherent to the PrateOn analysis software. 
     
       
         
           
               
             
               
                 TABLE 10 
               
             
            
               
                   
               
               
                 Apparent Kinetics of Anti-TNF alpha antibodies 
               
               
                 binding to Neutravidin Captured TNF alpha 
               
            
           
           
               
               
               
               
               
            
               
                   
                 BPC Number 
                 ka (1/Ms) 
                 kd (1/s) 
                 KD (nM) 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 BPC1499 
                 2.27E+06 
                 1.72E−05 
                 0.008 
               
               
                   
                 BPC1500 
                 2.06E+06 
                 3.00E−05 
                 0.015 
               
               
                   
                 BPC1501 
                 1.17E+06 
                 6.97E−05 
                 0.06 
               
               
                   
                 BPC1496 
                 6.33E+05 
                 4.04E−04 
                 0.639 
               
               
                   
                 BPC1494 
                 7.23E+05 
                 3.50E−04 
                 0.484 
               
               
                   
                 BPC1492 
                 7.89E+05 
                 3.21E−04 
                 0.407 
               
               
                   
                   
               
            
           
         
       
     
     This data is one set of two experiments which were carried out (second set not shown). The KD ranking of the data is representative of both data sets. 
     Example 20 
     Construction of Alternative Antibodies which Bind to Human TNFα 
     The DNA expression constructs encoding additional variable heavy regions with modifications in the CDR regions (as described in Rajpal et al. PNAS (2005) 102(24): pg 8466-8471) were prepared de novo by build up of overlapping oligonucleotides and similar molecular biology techniques to those described in Example 1. Examples of DNA sequences encoding the variable heavy domains of these variant antibodies are given in SED IQ NO: 81, 83, 85, 87, 89, 91, 93 and 95. The DNA expression constructs encoding additional variable light domain regions with modifications in the CDR regions (as described in Rajpal et al. PNAS (2005) 102(24): pg 8466-8471) were prepared de novo by build up of overlapping oligonucleotides and similar molecular biology techniques to those described in Example 1. Examples of DNA sequences encoding the variable light domains of these variant antibodies are given in SED IQ NO: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 and 137. Once constructed, the expression plasmids encoding the heavy and light chains were transiently co-transfected into HEK 293 6E cells. Expressed antibody were purified from the supernatant and assessed for activity using the methods similar to those described in Example 6. 
     Example 21 
     Construction of Expression Vectors for BPC2604 (Pascolizumab-YTE) 
     The pTT-based DNA expression constructs encoding the heavy chain of pascolizumab was engineered to include the following changes M252Y/S254T/T256E (EU index numbering) using the Quikchange protocol (Promega). 
     Example 22 
     Expression/Purification of Pasco and Pasco-YTE Vectors 
     Expression plasmids encoding the heavy and light chains of BPC2604 were transiently co-transfected into HEK 293 6E cells. Expressed antibody was purified from the bulk supernatant using a two step purification carried out by affinity chromatography and SEC using a 5 ml MabSelectSure column and Superdex 200 column on an AKTA Xpress. 
     Example 23 
     BIAcore Analysis of Pasco Vs. Pasco YTE for FcRn Binding 
     Antibodies were immobilised on a GLM chip (20 μg/ml in acetate pH4.5) by primary amine coupling. Human, cynomolgus, rat and mouse FcRn receptors used at 2048, 512, 128, 32 and 8 nM. 0 nM used for double referencing. Assay were carried out in HBS-EP pH7.4 and HBS-EP pH6.0 (FcRn receptor diluted in appropriate running buffer for each pH. The surface was regenerated for FcRn binding with 200 mM Tris pH9.0. Data was fitted to an equilibrium model, with R-max set to highest R-max obtained of any construct. The results are shown in Table 11 below and confirm that the YTE-modified pascolizumab (BPC2604) shows improved binding to FcRn at pH6.0 compared to pascolizumab. 
     
       
         
           
               
             
               
                 TABLE 11 
               
             
            
               
                   
               
               
                 Affinities of anti-IL-4 antibody constructs for Human and Cyno FcRn 
               
               
                 (n.a.b. is no analysable binding) 
               
            
           
           
               
               
               
            
               
                   
                 KD (nM) at pH 6.0: 
                 KD (nM) at pH 7.4: 
               
               
                   
                 R-max = 1020 
                 R-max = 1020 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                 Human 
                 Cyno 
                 Mouse 
                 Rat 
                 Human 
                 Cyno 
                 Mouse 
                 Rat 
               
               
                 Antibody 
                 Fc modification 
                 FcRn 
                 FcRn 
                 FcRn 
                 FcRn 
                 FcRn 
                 FcRn 
                 FcRn 
                 FcRn 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 BPC2604 
                 M252Y/S254T/T256E 
                 98 
                 92.1 
                 53.4 
                 66.0 
                 11600 
                 11100 
                 2160 
                 4330 
               
               
                 Pascolizumab 
                 None 
                 541 
                 505 
                 205 
                 228 
                 n.a.b 
                 n.a.b 
                 n.a.b 
                 n.a.b 
               
               
                   
               
            
           
         
       
     
     Example 24 
     PK Studies with Pasco Vs. Pasco-YTE 
       FIG. 6  shows the average dose normalised plasma concentrations of pascolizumab-YTE (BPC2604)) in female cynomolgus monkeys and pascolizumab in male cynomolgus monkeys following a single intravenous (1 hr infusion) administration at a target dose of 1 mg/kg. The data for BPC2604 and pascolizumab were generated in separate studies. Plasma antibody concentrations for pascolizumab and BPC2604 were assessed by chemi-luminescence ELISA using IL-4 as the capture reagent and anti-human IgG (Fc specific)-HRP conjugate as the detection reagent. The validated range for the assay was 50-5000 ng/mL. The results are shown in  FIG. 6 . Both compounds had similar Cmax but BPC2604 had a 3-fold lower plasma clearance resulting in 3-fold increase in AUC and 2-fold increase in half-life (T½). 
     Example 25 
     Formulation Studies at 5 mg/ml 
     The stability of adalimumab and the TNF-alpha variant BPC1494 in two formulations was compared. Formulation ‘A’ (citrate-phosphate buffer) is the marketed adalimumab formulation made up of 6.16 mg/ml Sodium chloride+0.30 mg/ml Sodium citrate monobasic+1.30 mg/mL Citric acid monohydrate+12 mg/ml Mannitol+0.86 mg/mL Monobasic sodium phosphate dihydrate+1.53 mg/mL Dibasic sodium phosphate dihydrate+1.0 mg/ml PS80 at pH 5.2. 
     Formulation ‘B’ (acetate buffer) is composed of 6.81 mg/mL (50 mM) Sodium Acetate trihydrate+10 mg/mL (1% w/v) Arginine+0.0186 mg/mL (0.05 mM) EDTA+2.98 mg/mL (51 mM) Sodium Chloride+0.2 mg/mL (0.02% w/v) Polysorbate 80, adjusted to pH 5.5 using HCl or NaOH. 
     The TNF-alpha variant BPC1494 material used in this study was made in a Chinese Hamster Ovary (CHO DG44) cell line and purified using a two step process involving mAb Select Sure followed by Superdex column 200 μg. Adalimumab (Product code NDC 0074-3799-02, Lot number 91073LX40) manufactured by Abbott Laboratories was used. 
     Adalimumab was re-formulated into Formulation ‘B’ by overnight dialysis at 5° C. using a 10 KDa Slide—A—Lyzer cassette (Product Number 66830, Lot Number LJ150514); produced by Thermo Scientific (Rockford, Ill.; USA). This experiment was carried out at a different time point to the other three formulations. Both Adalimumab in Formulations ‘A’ and ‘B’ were diluted to 5 mg/mL using their respective formulation buffers. The TNF-alpha variant BPC1494 molecule was also formulated in Formulations A and B at ˜5 mg/mL. A total of 4 samples were filtered through a MillexGV 0.22 um filter under a clean laminar flow condition before being transferred into labelled pre-sterilized glass vials and incubated at 5° C., 25° C. and 40° C. for up to 14 weeks. Samples were taken at selected time points and analysed using SEC-HPLC (Table 12), cIEF (Table 13). Other assays as described below were also carried out to assess the stability of the antibodies. 
     Appearance by Visual Observation 
     Samples were inspected for clarity under daylight conditions. Both antibodies in each formulation remained unchanged (clear colourless solution) after 14 weeks storage at 5° C., 25° C. and 40° C. 
     Protein Concentration (A280 nm) Measurement 
     Protein concentration was measured using a nanodrop spectrometer, which is indicative of protein stability. The extinction coefficient for adalimumab is 1.46 and for TNF-alpha variant BPC1494 is 1.48. There was no significant difference in the results after 14 weeks storage at 5° C., 25° C. and 40° C. 
     pH 
     pH was measured for all samples stored under different storage conditions to determine whether any significant pH drifts had occurred. All results remained within assay variability after 14 weeks storage at 5° C., 25° C. and 40° C. 
     Size Exclusion Chromatography (SEC) 
     This method separates soluble protein molecules in the solution based on size and not molecular weight. In theory, small molecules will penetrate every small pore of the stationary phase and hence will elute later. The chromatogram obtained enables the determination of percentage area of aggregates, monomer and low molecular weight (MW) fragments. The presence of aggregates and/or low molecular weight species is indicative of protein degradation. Increased stability corresponds to a high percentage of monomeric species (Mono) together with a low percentage of Total Aggregates (TA) and Total Low Molecular weight Fragments (TLMWF). 
     SEC-HPLC data (Table 12) shows that the TNF-alpha variant BPC1494 was relatively more stable in formulation ‘B’ compared to formulation A after storage at 25° C. and 40° C. for 14 weeks. Furthermore, TNF-alpha variant BPC1494 was relatively more stable, or at least as stable as adalimumab in formulation A. The results for adalimumab in formulation B are all within 5% TA and/or TLMWF. Therefore, formulation B has advantages over formulation A for both TNF-alpha variant BPC1494 and adalimumab. 
     For example, Table 12 shows that after storage at 25° C. for 8 weeks, TNF-alpha variant BPC1494 in formulation A has 2.3% TLMWF while formulation B produced only 1.5%. Furthermore, TNF-alpha variant BPC1494 in formulation B was relatively more stable than adalimumab in formulation A (1.8% TLMWF). Similarly, at the 14 week time point at 25° C., 3.15% TLMWF was observed for TNF-alpha variant BPC1494 in formulation ‘A’ compared to 2.3% TLMWF in formulation ‘B’. Furthermore, TNF-alpha variant BPC1494 in ‘B’ was relatively more stable than adalimumab in formulation A (3.4% TLMWF). A similar trend for TLMWF was observed for both molecules on incubation at 40° C. for 4 weeks (adalimumab in ‘A’: 3.6%; TNF-alpha variant BPC1494 in ‘A’: 4.1%; TNF-alpha variant BPC1494 in ‘B’: 2.6%). 
     Also, results for Total Aggregate (TA) show that at 14 weeks at 25° C., the TNF-alpha variant BPC1494 was relatively more stable in ‘B’ (0.3%) than in ‘A’ (0.5%); and relatively more stable than adalimumab in formulation A (0.4%). 
     Capillary Iso-Electric Focusing (c-IEF) 
     This technique is used for determining the charge profile of molecules. A broad pI range reflects greater charge heterogeneity of the Product and in addition a broad pI range may be indicative of degradation. Typically the number of peaks will increase with increased degradation. The C-IEF data of Table 12 supports the SEC findings in Table 13. 
     The % area of main isoform (% AMI) was comparable between adalimumab in formulation A and TNF-alpha variant BPC1494 in formulation B at Weeks 8 and 14 at 25° C. (56.0-57.7 and 53.2 respectively). At these time points and temperature, formulation B shows a slight advantage over ‘A’ for TNF-alpha variant BPC1494. 
     Similarly, adalimumab is relatively more stable in formulation ‘B’ than in formulation ‘A’ (see Week 4 data). For example, increased changes in charge heterogeneity (i.e. increase in number of peaks) were observed for adalimumab incubated for up to 4 weeks at 40° C. in formulation ‘A’ compared to formulation ‘B’ (8 peaks and 6 peaks respectively). TNF-alpha variant BPC1494 showed a more consistent charge heterogeneity of 5 peaks at all timepoints and temperatures. 
     Functional Binding Assay 
     The binding activity of adalimumab and TNF-alpha variant BPC1494 in the two formulations was assessed by Biacore. Over a 14 week period of storage at 5° C., 25° C. and 40° C., the samples showed similar % binding within assay variability. 
     Hence, it can be concluded that formulation ‘B’ can serve as an alternative to formulation ‘A’ in a clinical setting without compromising the stability of the protein and potentially eliminating the pain associated with the marketed adalimumab formulation (A). 
     Importantly, this data shows that not only does the acetate formulation (B) improve the stability of the TNF-alpha variant BPC1494 compared to the citrate-phosphate formulation (A); but the acetate formulation is comparable or slightly better than the citrate-phosphate formulation when stabilising adalimumab. 
     
       
         
           
               
             
               
                 TABLE 12 
               
             
            
               
                   
               
               
                 SEC-HPLC of adalimumab and TNF-alpha variant BPC1494 in Formulation ‘A’ and ‘B’ at 5° C., 25° C. and 40° C. 
               
               
                 TLMWF: Total Low Molecular Weight Fragment; Mono: Monomer; TA: Total Aggregate. N = 2 
               
            
           
           
               
               
               
               
               
               
            
               
                 Condition 
                 Initial 
                 Week 2 
                 Week 4 
                 Week 8 
                 Week 14 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 ° C. 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
               
               
                   
               
            
           
           
               
            
               
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.30 
                 99.57 
                 0.13 
                 NT 
                 0.27 
                 99.58 
                 0.15 
                 0.32 
                 99.48 
                 0.19 
                 0.49 
                 99.28 
                 0.23 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 0.23 
                 99.55 
                 0.22 
                 0.20 
                 99.57 
                 0.23 
                 0.30 
                 97.87 
                 1.83 
                 0.43 
                 96.16 
                 3.41 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 40° C. 
                   
                 0.24 
                 96.86 
                 2.91 
                 0.29 
                 96.06 
                 3.65 
                 NT 
                 NT 
               
            
           
           
               
            
               
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.34 
                 99.47 
                 0.18 
                 NT 
                 0.23 
                 99.46 
                 0.31 
                 0.23 
                 99.53 
                 0.24 
                 NT 
               
            
           
           
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 NT 
                 NT 
                 NT 
                 NT 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 40° C. 
                   
                 0.22 
                 97.60 
                 2.18 
                 0.24 
                 95.7 
                 4.06 
                 0.34 
                 94.92 
                 4.74 
                 NT 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.28 
                 99.72 
                 0.00 
                 NT 
                 0.27 
                 99.73 
                 0.00 
                 0.31 
                 99.59 
                 0.10 
                 0.44 
                 99.41 
                 0.15 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 0.28 
                 99.59 
                 0.13 
                 0.28 
                 98.50 
                 1.22 
                 0.39 
                 97.32 
                 2.30 
                 0.47 
                 96.38 
                 3.15 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 40° C. 
                   
                 0.34 
                 96.71 
                 2.96 
                 0.85 
                 95.09 
                 4.07 
                 NT 
                 NT 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.29 
                 99.71 
                 0.00 
                 NT 
                 0.27 
                 99.73 
                 0.00 
                 0.28 
                 99.53 
                 0.19 
                 0.29 
                 99.59 
                 0.12 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 0.27 
                 99.58 
                 0.15 
                 0.26 
                 99.62 
                 0.12 
                 0.30 
                 98.16 
                 1.54 
                 0.30 
                 97.39 
                 2.31 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 40° C. 
                   
                 0.28 
                 99.40 
                 0.31 
                 0.25 
                 97.17 
                 2.58 
                 NT 
                 NT 
               
               
                   
               
               
                 NT = Not Tested 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 13 
               
               
                   
               
               
                 CE-IEF of adalimumab and TNF-alpha variant BPC1494 in 
               
               
                 Formulation ‘A’ and ‘B’ at 5° C., 25° C. and 40° C. N = 2 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Initial 
                 Week 2 
                 Week 4 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Condition 
                   
                   
                 % 
                   
                   
                   
                 % 
                   
                   
                   
                 % 
                   
               
               
                 ° C. 
                 pI R 
                 pMI 
                 AMI 
                 No P 
                 pI R 
                 pMI 
                 AMI 
                 No P 
                 pI R 
                 pMI 
                 AMI 
                 No P 
               
               
                   
               
            
           
           
               
            
               
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.52-8.98 
                 8.72 
                 62.8 
                 6 
                 NT 
                 8.52-8.96 
                 8.72 
                 62.2 
                 6 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 8.58-9.05 
                 8.81 
                 52.4 
                 6 
                 8.50-8.96 
                 8.72 
                 60.3 
                 6 
               
               
                 40° C. 
                   
                 8.53-9.06 
                 8.79 
                 41.4 
                 8 
                 8.49-9.05 
                 8.71 
                 43.3 
                 8 
               
            
           
           
               
            
               
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.57-9.07 
                 8.79 
                 60.5 
                 6 
                 NT 
                 8.55-9.02 
                 8.76 
                 59.9 
                 6 
               
            
           
           
               
               
               
               
            
               
                 25 C 
                   
                 NT 
                 NT 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 40° C. 
                   
                 8.53-9.02 
                 8.75 
                 53.2 
                 6 
                 8.53-9.02 
                 8.75 
                 47.9 
                 6 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.18-8.64 
                 8.50 
                 57.6 
                 5 
                 NT 
                 8.19-8.64 
                 8.50 
                 60.2 
                 5 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 8.20-8.69 
                 8.53 
                 57.7 
                 5 
                 8.19-8.62 
                 8.50 
                 57.9 
                 5 
               
               
                 40° C. 
                   
                 8.21-8.70 
                 8.54 
                 50.0 
                 5 
                 8.00-8.60 
                 8.50 
                 37.0 
                 5 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.19-8.65 
                 8.50 
                 58.3 
                 5 
                 NT 
                 8.20-8.65 
                 8.51 
                 59.3 
                 5 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 25° C. 
                   
                 8.22-8.70 
                 8.54 
                 57.8 
                 5 
                 8.20-8.65 
                 8.51 
                 57.1 
                 5 
               
               
                 40° C. 
                   
                 8.22-8.70 
                 8.54 
                 50.7 
                 5 
                 8.01-8.62 
                 8.51 
                 38.0 
                 5 
               
               
                   
               
            
           
           
               
               
               
            
               
                   
                 Week 8 
                 Week 14 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                 Condition 
                   
                   
                 % 
                   
                   
                   
                 % 
                   
               
               
                   
                 ° C. 
                 pI R 
                 pMI 
                 AMI 
                 No P 
                 pI R 
                 pMI 
                 AMI 
                 No P 
               
               
                   
                   
               
            
           
           
               
               
            
               
                   
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.53-9.00 
                 8.74 
                 62.2 
                 6 
                 8.48-8.95 
                 8.71 
                 60.0 
                 5 
               
               
                   
                 25° C. 
                 8.51-9.00 
                 8.74 
                 57.7 
                 6 
                 8.51-8.98 
                 8.73 
                 53.2 
                 5 
               
            
           
           
               
               
               
               
            
               
                   
                 40° C. 
                 NT 
                 NT 
               
            
           
           
               
               
            
               
                   
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.49-8.96 
                 8.72 
                 61.0 
                 5 
                 NT 
               
            
           
           
               
               
               
               
            
               
                   
                 25 C 
                 NT 
                 NT 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                 40° C. 
                 8.49-9.07 
                 8.72 
                 39.8 
                 6 
                 NT 
               
            
           
           
               
               
            
               
                   
                 TNF-alpha variant BPC1494 in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.21-8.67 
                 8.51 
                 59.1 
                 5 
                 8.17-8.62 
                 8.49 
                 58.8 
                 5 
               
               
                   
                 25° C. 
                 8.20-86.6 
                 8.51 
                 54.5 
                 5 
                 8.17-8.61 
                 8.49 
                 52.1 
                 5 
               
            
           
           
               
               
               
               
            
               
                   
                 40° C. 
                 NT 
                 NT 
               
            
           
           
               
               
            
               
                   
                 TNF-alpha variant BPC1494 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.21-8.67 
                 8.52 
                 59.4 
                 5 
                 8.18-8.65 
                 8.50 
                 58.5 
                 5 
               
               
                   
                 25° C. 
                 8.21-8.67 
                 8.52 
                 56.0 
                 5 
                 8.18-8.64 
                 8.50 
                 53.2 
                 5 
               
            
           
           
               
               
               
               
            
               
                   
                 40° C. 
                 NT 
                 NT 
               
               
                   
                   
               
               
                   
                 NT = Not Tested; 
               
               
                   
                 pI R: Pi Range; 
               
               
                   
                 pMI: pI of Main Isoform; 
               
               
                   
                 % AMI: % Area Main Isoform; 
               
               
                   
                 NoP: Number of Peaks. 
               
            
           
         
       
     
     Example 26 
     Formulation Studies at 50 mg/ml 
     As shown in the previous example 25, adalimumab and TNF-alpha variant BPC1494 at 5 mg/mL in formulation ‘B’ can serve as an alternative to formulation ‘A’. This example is focused on comparing the stability of adalimumab in its marketed formulation ‘A’ compared to formulation ‘B’ and other TNF-alpha variants at 50 mg/ml. 
     Two samples of TNF-alpha variant BPC1494 were analysed, one expressed in CHO DG44 cells and one expressed in CHOK1 cells. A second TNF-alpha variant BPC1496 was made in a CHO-DG44 cell line. All three samples were expressed and purified using mAb Select Sure. In contrast to Example 25, no Superdex column step was carried out. Adalimumab (Product code N 00515-01, Lot number 02136XH12) manufactured by Abbott Laboratories, as in Example 25. Adalimumab was formulated in formulations ‘A’ (as purchased) and ‘B’ (by buffer exchange) as described above in Example 25, and the TNF-alpha variants (BPC1494 and 1496) were formulated in ‘B’, all at ˜50 mg/mL (total of 5 samples). The samples were filtered with MillexGV 0.22 um filter under clean laminar flow conditions before being transferred into labelled pre-sterilized glass vials and incubated at 5° C. and 40° C. for up to 9 weeks. At selected time-points, samples were taken and analysed using SEC-HPLC (Table 14), cIEF (Table 15). Other assays as described below were also carried out. 
     Appearance by Visual Observation. 
     Samples were observed for clarity under daylight conditions. Both antibodies in both formulations remained unchanged (clear colourless solution) after 9 weeks storage at 5° C. and 40° C. 
     Protein Concentration (A280 nm) Measurement 
     Protein concentration was measured using a nanodrop spectrometer, which is indicative of protein stability. There was no significant difference in the results after 9 weeks storage at 5° C. and 40° C. 
     Size Exclusion Chromatography (SEC) 
     SEC-HPLC data (Table 13) showed that adalimumab at 50 mg/ml was relatively more stable in formulation ‘B’ compared to formulation ‘A’ after storage at 40° C. for 9 weeks. Also, the TNF-alpha variants (BPC1494 and 1496) were relatively as stable or more stable in ‘B’ as adalimumab in B′. No comparison between the variants in ‘A’ and ‘B’ was carried out. 
     Note that the Initial TA levels for the TNF-alpha variants were relatively higher than for adalimumab. Therefore, the results include a % change column at the right hand side to compare the changes from Initial to Week 9 at 40° C. For example, table 13 shows that after 9 week storage, the percentage change in total low molecular weight fragment (TLMWF) in formulation ‘B’ was between 3.82-4.96% compared to 6.08% in formulation ‘A’. Similarly, the monomer percentage change in formulation ‘A’ was greater for adalimumab than for ‘B’ (7.54 and 4.52% respectively). The TNF-alpha variants in ‘B’ were all relatively at least as stable or more stable as adalimumab in formulation ‘A’ (% change at Week 9). The results at week 4 for all samples are within the 5% TA and/or TLMWF allowance for a commercial product. Therefore, ‘B’ has advantages over ‘A’ for both TNF-alpha variants and adalimumab at 50 mg/ml. 
     In particular, the TNF-alpha variant BCP1496 showed a low TLMWF value of 3.86 at Week 9 at 40° C. 
     Capillary Iso-Electric Focusing (c-IEF) 
     C-IEF data (Table 15) supports the findings in Table 14. 
     Formulation B shows a reduced % change of % AMI at week 9 for adalimumab as compared to Formulation A (23.53 and 27.57 respectively). 
     The TNF-alpha variants in ‘B’ are more stable in terms of charge heterogeneity (i.e. increase in number of peaks) than adalimumab (in both ‘A’ and ‘B’). For example, at Week 9 there were 5 and 6 peaks for each of the variants; and 6 and 9 peaks for adalimumab, at 5° C. and 40° C. respectively. 
     In particular, the TNF-alpha variant BCP1496 and adalimumab, both in ‘B’, showed a low % change in % AMI at week 9 of 25.83 and 23.53 respectively. The relatively higher % change in % AMI at week 9 for the TNF-alpha variant BCP1496 (CHO DG44) of 38.13 may be due to the relatively high initial % AMI of 75.03. 
     Functional Binding Assay (ELISA) 
     The biological activity of adalimumab and the TNF-alpha variants in the two formulations was assessed by Biacore. Over the 9 week period of storage at 5° C. and 40° C., the samples showed the same % binding within assay variability. 
     Hence, it can be concluded that formulation ‘B’ can serve as an alternative to formulation ‘A’ in a clinical setting without compromising the stability of the antibody at 50 mg/mL dosage strength. 
     
       
         
           
               
             
               
                 TABLE 14 
               
               
                   
               
               
                 SEC-HPLC of adalimumab and TNF-alpha variants BPC1494 and 1496 in 
               
               
                 Formulations ‘A’ and ‘B’ at 5° C., 25° C. and 40° C. 
               
               
                 TLMWF—Total Low Molecular Weight Fragment; Mono—Monomer; 
               
               
                 TA—Total Aggregate. N = 2 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Condition 
                 Initial 
                 Week 1 
                 Week 2 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 ° C. 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
               
               
                   
               
            
           
           
               
            
               
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.30 
                 99.62 
                 0.08 
                 0.30 
                 99.54 
                 0.16 
                 0.32 
                 99.53 
                 0.15 
               
               
                 40° C.  
                   
                   
                   
                 0.39 
                 99.13 
                 0.48 
                 0.51 
                 99.03 
                 0.46 
               
            
           
           
               
            
               
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.42 
                 99.45 
                 0.13 
                 0.34 
                 99.49 
                 0.17 
                 0.38 
                 99.45 
                 0.16 
               
               
                 40° C. 
                   
                   
                   
                 0.41 
                 99.36 
                 0.23 
                 0.48 
                 99.23 
                 0.29 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 (CHO DG44) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 2.76 
                 97.13 
                 0.11 
                 2.65 
                 97.25 
                 0.09 
                 3.29 
                 96.45 
                 0.25 
               
               
                 40° C. 
                   
                   
                   
                 2.96 
                 96.74 
                 0.29 
                 2.98 
                 96.70 
                 0.32 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 (CHOK1) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 2.35 
                 97.64 
                 0.00 
                 2.32 
                 97.69 
                 0.00 
                 2.36 
                 97.64 
                 0.00 
               
               
                 40° C. 
                   
                   
                   
                 2.67 
                 97.09 
                 0.24 
                 2.79 
                 96.99 
                 0.22 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1496 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 1.19 
                 98.78 
                 0.04 
                 1.47 
                 98.49 
                 0.04 
                 1.62 
                 98.34 
                 0.03 
               
               
                 40° C. 
                   
                   
                   
                 1.75 
                 97.99 
                 0.26 
                 1.46 
                 98.27 
                 0.27 
               
               
                   
               
            
           
           
               
               
               
               
            
               
                 Condition 
                 Week 4 
                 Week 9 
                 % Change at Week 9 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 ° C. 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
                 TA 
                 Mono 
                 TLMWF 
               
               
                   
               
            
           
           
               
            
               
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.29 
                 99.51 
                 0.21 
                 0.34 
                 99.49 
                 0.17 
                 1.45 
                 7.54 
                 6.08 
               
               
                 40° C.  
                 0.54 
                 98.77 
                 0.69 
                 1.75 
                 92.08 
                 6.16 
               
            
           
           
               
            
               
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 0.35 
                 99.42 
                 0.23 
                 0.38 
                 99.44 
                 0.18 
                 0.46 
                 4.52 
                 4.06 
               
               
                 40° C. 
                 0.54 
                 98.85 
                 0.61 
                 0.88 
                 94.93 
                 4.19 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 (CHO DG44) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 2.66 
                 97.18 
                 0.16 
                 2.83 
                 97.05 
                 0.12 
                 1.32 
                 6.28 
                 4.96 
               
               
                 40° C. 
                 2.96 
                 96.36 
                 0.68 
                 4.08 
                 90.85 
                 5.07 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 (CHOK1) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 2.33 
                 97.67 
                 0.00 
                 2.56 
                 97.40 
                 0.04 
                 2.56 
                 7.42 
                 4.88 
               
               
                 40° C. 
                 3.17 
                 96.20 
                 0.63 
                 4.91 
                 90.22 
                 4.88 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1496 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 1.71 
                 98.15 
                 0.14 
                 1.92 
                 97.95 
                 0.13 
                 1.45 
                 5.28 
                 3.82 
               
               
                 40° C. 
                 1.40 
                 98.05 
                 0.54 
                 2.64 
                 93.50 
                 3.86 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 15 
               
               
                   
               
               
                 CE-IEF of adalimumab and TNF-alpha variants BPC1494 and 1496 in 
               
               
                 Formulations ‘A’ and ‘B’ at 5° C., 25° C. and 40° C. N = 2 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Initial 
                 Week 1 
                 Week 2 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Condition 
                   
                   
                 % 
                   
                   
                   
                 % 
                   
                   
                   
                 % 
                   
               
               
                 ° C. 
                 pI R 
                 pMI 
                 AMI 
                 NoP 
                 pI R 
                 pMI 
                 AMI 
                 NoP 
                 pI R 
                 pMI 
                 AMI 
                 NoP 
               
               
                   
               
            
           
           
               
            
               
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.55-9.01 
                 8.76 
                 58.67 
                 6 
                 8.56-9.00 
                 8.74 
                 58.28 
                 6 
                 8.57-9.01 
                 8.75 
                 57.42 
                 6 
               
               
                 40° C. 
                   
                   
                   
                   
                 8.53-9.01 
                 8.75 
                 56.18 
                 6 
                 8.52-9.00 
                 8.75 
                 51.82 
                 6 
               
            
           
           
               
            
               
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.53-9.02 
                 8.76 
                 57.91 
                 6 
                 8.53-9.01 
                 8.76 
                 59.51 
                 6 
                 8.52-9.01 
                 8.76 
                 56.85 
                 6 
               
               
                 40° C. 
                   
                   
                   
                   
                 8.53-9.02 
                 8.76 
                 55.52 
                 6 
                 8.52-9.00 
                 8.75 
                 51.7 
                 6 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 (CHO DG44) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.22-8.68 
                 8.53 
                 75.03 
                 5 
                 8.29-8.68 
                 8.52 
                 76.13 
                 5 
                 8.28-8.68 
                 8.52 
                 75.11 
                 5 
               
               
                 40° C. 
                   
                   
                   
                   
                 8.22-8.66 
                 8.51 
                 70.92 
                 5 
                 8.20-8.67 
                 8.51 
                 64.52 
                 5 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1494 (CHOK1) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.23-8.68 
                 8.53 
                 63.75 
                 5 
                 8.22-8.68 
                 8.53 
                 63.69 
                 5 
                 8.22-8.67 
                 8.52 
                 63.37 
                 5 
               
               
                 40° C. 
                   
                   
                   
                   
                 8.21-8.66 
                 8.51 
                 60.57 
                 5 
                 8.21-8.65 
                 8.51 
                 56.21 
                 5 
               
            
           
           
               
            
               
                 TNF-alpha variant BPC1496 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                  5° C. 
                 8.53-8.89 
                 8.75 
                 65.48 
                 5 
                 8.52-8.88 
                 8.74 
                 64.01 
                 5 
                 8.51-8.88 
                 8.74 
                 67.57 
                 5 
               
               
                 40° C. 
                   
                   
                   
                   
                 8.51-8.87 
                 8.73 
                 60.52 
                 5 
                 8.51-8.87 
                 8.74 
                 57.82 
                 5 
               
               
                   
               
            
           
           
               
               
               
               
            
               
                   
                   
                   
                 % 
               
               
                   
                 Week 4 
                 Week 9 
                 Change 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                 Condition 
                   
                   
                 % 
                   
                   
                   
                 % 
                   
                 Week 9 
               
               
                   
                 ° C. 
                 pI R 
                 pMI 
                 AMI 
                 NoP 
                 pI R 
                 pMI 
                 AMI 
                 NoP 
                 % AMI 
               
               
                   
                   
               
            
           
           
               
               
            
               
                   
                 adalimumab in formulation ‘A’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.54-9.01 
                 8.75 
                 59.45 
                 6 
                 8.55-9.02 
                 8.77 
                 60.37 
                 6 
                 27.57 
               
               
                   
                 40° C. 
                 8.53-9.02 
                 8.75 
                 47.24 
                 6 
                 8.36-9.02 
                 8.77 
                 31.10 
                 9 
               
            
           
           
               
               
            
               
                   
                 adalimumab in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.53-9.01 
                 8.75 
                 59.00 
                 6 
                 8.54-9.02 
                 8.77 
                 59.62 
                 6 
                 23.53 
               
               
                   
                 40° C. 
                 8.53-9.01 
                 8.75 
                 47.07 
                 6 
                 8.36-9.02 
                 8.77 
                 34.38 
                 9 
               
            
           
           
               
               
            
               
                   
                 TNF-alpha variant BPC1494 (CHO DG44) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.28-8.68 
                 8.52 
                 73.76 
                 5 
                 8.24-8.69 
                 8.53 
                 75.17 
                 5 
                 38.13 
               
               
                   
                 40° C. 
                 8.23-8.68 
                 8.53 
                 58.40 
                 5 
                 8.06-8.69 
                 8.54 
                 36.9 
                 6 
               
            
           
           
               
               
            
               
                   
                 TNF-alpha variant BPC1494 (CHOK1) in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.22-8.68 
                 8.52 
                 62.32 
                 5 
                 8.24-8.70 
                 8.53 
                 63.88 
                 5 
                 33.09 
               
               
                   
                 40° C. 
                 8.22-8.67 
                 8.52 
                 50.64 
                 5 
                 8.06-8.68 
                 8.54 
                 30.66 
                 6 
               
            
           
           
               
               
            
               
                   
                 TNF-alpha variant BPC1496 in formulation ‘B’ 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                  5° C. 
                 8.52-8.88 
                 8.75 
                 67.06 
                 5 
                 8.53-8.89 
                 8.76 
                 68.75 
                 5 
                 25.83 
               
               
                   
                 40° C. 
                 8.51-8.87 
                 8.74 
                 51.37 
                 5 
                 8.36-8.88 
                 8.76 
                 39.65 
                 6 
               
               
                   
                   
               
               
                   
                 NT = Not Tested; 
               
               
                   
                 pI R—Pi Range; 
               
               
                   
                 pMI—pI of Main Isoform; 
               
               
                   
                 % AMI—% Area Main Isoform; 
               
               
                   
                 NoP—Number of Peaks. 
               
            
           
         
       
     
     Example 27 
     Plasma Concentrations of BPC1494 Following Subcutaneous Administration in the Male Cynomolgus Monkey 
     In a repeat dose pharmacokinetic study BPC1494 was administered sub-cutaneously weekly or biweekly for 4 weeks at 30 or 100 mg/kg to male cynomolgus monkeys. For group 2 (n=3), the animals were administered 2×30 mg/kg doses on day 1 (approximately 1 hour apart) followed by a single 30 mg/kg dose on days 8, 15 and 22. For group 3 (n=3), the animals were administered with 2×30 mg/kg doses on day 1 (approximately 1 hour apart) followed by a single 30 mg/kg dose on day 15. For group 4 (n=3), the animals were administered with 2×100 mg/kg doses on day 1 (approximately 1 hour apart) followed by a single 100 mg/kg dose on day 15. Plasma samples were taken at intervals throughout the dosing and recovery phases of the study. 
     Plasma samples were analyzed for BPC1494 using a qualified analytical method based on sample dilution followed by immunoassay analysis Plasma samples were analyzed for BPC1494 or BPC1492. The method used 10 μg/ml biotinylated recombinant human TNF-alpha as the capture antigen and a 1:100 dilution of AlexaFluor 647-labelled anti-human IgG (Fc specific) antibody as the detection antibody (G18-145). The lower limit of quantification (LLQ) for BPC1494 was 1 μg/mL using a 50 μL aliquot of 100-fold diluted monkey plasma with a higher limit of quantification (HLQ) of 100 μg/mL. The computer systems that were used on this study to acquire and quantify data included Gyrolab Workstation Version 5.2.0, Gyrolab Companion version 1.0 and SMS2000 version 2.3. PK analysis was performed by non-compartmental pharmacokinetic analysis using WinNonlin Enterprise Pheonix version 6.1. 
     Pharmacokinetic data is presented in Table 16 with parameters determined from last dose received on Week 4 to the time point (t) 840 hours post dosing for 30 mg/kg/week dose group (2) and last dose received on Week 3 to the time point (t) 1008 hours post dosing for 30 &amp; 100 mg/kg/biweekly dose groups (3 and 4). 
     
       
         
           
               
             
               
                 TABLE 16 
               
             
            
               
                   
               
               
                 Individual and Mean Pharmacokinetic Parameters for BPC1494 in the 
               
               
                 Male Cynomolgus Monkey Following Subcutaneous Dosing of BPC1494 at 
               
               
                 30 mg/kg/week or 30 and 100 mg/kg/biweekly over a 4-Week Investigative Study 
               
            
           
           
               
               
            
               
                   
                 Pharmacokinetic Parameters b 
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 Dose 
                   
                   
                   
                 Median 
                   
                   
                 Estimated c 
                 Estimated c 
               
               
                 (mg/kg/ 
                 Animal 
                 AUC0-t 
                 Cmax 
                 Tmax 
                 t½ 
                 MRT 
                 CL_F 
                 Vz_F 
               
               
                 biweekly) 
                 Number 
                 (mg · h/mL) 
                 (mg/mL) 
                 (h) 
                 (h) 
                 (h) 
                 (mL/h/kg) 
                 (mL/kg) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                  30a 
                 P12M-272 
                 923 
                 1.51 
                 168  
                 616 
                 367 
                 0.125 
                 111   
               
               
                   
                 P12M-273 
                 758 
                 1.29 
                 168  
                 604 
                 368 
                 0.141 
                 123   
               
               
                   
                 P12M-274d 
                   21.3 
                 0.135 
                 24 
                 226 
                 142 
                 3.01 
                 978   
               
               
                   
                 Mean 
                 841 
                 1.40 
                 168  
                 610 
                 367 
                 0.133 
                 117   
               
               
                   
                   
                 (568) 
                 (0.977) 
                   
                 (482) 
                 (292) 
                 (1.09) 
                 (404)   
               
               
                 30 
                 P12M-275 
                 743 
                 1.08 
                 24 
                 420 
                 419 
                 0.115 
                 69.5 
               
               
                   
                 P12M-276 
                 538 
                 2.31 
                 48 
                 197 
                 307 
                 0.141 
                 40.2 
               
               
                   
                 P12M-277d 
                 239 
                 1.09 
                 24 
                 123 
                 189 
                 0.217 
                 38.6 
               
               
                   
                 Mean 
                 641 
                 1.70 
                 36 
                 309 
                 363 
                 0.128 
                 54.9 
               
               
                   
                   
                 (507) 
                 (1.49) 
                 (24) 
                 (247) 
                 (305) 
                 (0.158) 
                 (49.4) 
               
               
                 100  
                 P12M-278 
                 2760  
                 5.89 
                 24 
                 398 
                 374 
                 0.0998 
                 57.3 
               
               
                   
                 P12M-279 
                 2480  
                 5.21 
                 72 
                 332 
                 362 
                 0.131 
                 62.9 
               
               
                   
                 P12M-280 
                 2080  
                 4.10 
                 72 
                 331 
                 364 
                 0.123 
                 58.8 
               
               
                   
                 Mean 
                 2440  
                 5.07 
                 72 
                 354 
                 367 
                 0.118 
                 59.7 
               
               
                   
               
               
                 aGroup 2 animals received 30 mg/kg weekly for 4 weeks 
               
               
                 b) Pharmacokinetic parameters determined from last dose received on Week 4 to the time point (t) 840 hours post dosing for 30 mg/kg/week and last dose received on Week 3 to the time point (t)1008 hours post dosing for 30 &amp; 100 mg/kg/biweekly 
               
               
                 c) Cl_F and Vz_F are estimates due to elimination phase following multiple doses and steady state not yet achieved. Parameter estimates have been calculated from i) using AUC0-168 or 336, ii) extrapolation of data from week 1 based on half-life and iii) using total dose over the defined sampling with AUC0-inf 
               
               
                 dAnimal 274 and 277 excluded from mean pharmacokinetic calculations based on scientific judgment that these animals are likely to be exhibiting an anti-drug antibody response. 
               
               
                 Mean data shown in parentheses are inclusive of these animals. 
               
            
           
         
       
     
     Example 28 
     SPR Binding Analysis of FcRn to Protein L Captured Anti-TNFα mAbs 
     The study was carried out using the ProteOn™ XPR36 (BioRad™) biosensor machine, a surface plasmon based machine designed for label free kinetic/affinity measurements. Protein L was immobilised on a GLM chip (BioRad, Cat No: 176-5012) by primary amine coupling. This surface was then used to capture the humanised antibodies, human and cyno FcRn (both in-house materials) was then used as analytes at 2048 nM, 512 nM, 128 nM, 32 nM, and 8 nM, an injection of buffer alone (i.e. 0 nM) used to double reference the binding curves. Regeneration of the protein L surface was carried out using Glycine-HCl pH1.5. The assay was run at 25° C. and run in HBS-EP pH7.4 and HBS-EP pH6.0 with human or cynomolgus FcRn diluted in appropriate buffer. Affinities were calculated using the Equilibrium model, inherent to the PrateOn analysis software, using a “Global R-max” for binding at pH6.0 and the R-max from binding at pH6.0 for affinity calculation at pH7.4. Since the binding curves did not reach saturation at pH7.4, the values obtained are unlikely to be true affinities however were used to rank the binding of the antibodies tested. 
     The binding affinity of different batches of BPC1492, BPC1494 and BPC1496 for human FcRn was compared using antibodies captures by Protein L. Table 17 shows the results from a series of experiments using this format. The data confirms that BPC1494 and BPC1496 have an improved affinity for recombinant human FcRn compared to BPC1492 at both pH6.0 and pH7.4. The fold improvement in binding affinity of BPC1494 for FcRn compared to BPC1492 differs from experiment to experiment due to changes in the Protein L activity on the capture. However, in the experiments shown in Table 17, the fold improvement in binding affinity at pH6.0 ranges between 3.5-fold and 16.3-fold. It was not possible to determine the fold improvement in binding affinity at pH7.4 due to the weak binding activity of human IgG for FcRn at neutral pH. 
     The binding affinity of different batches of BPC1492, BPC1494 and BPC1496 for cynomolgus FcRn was also compared using antibodies captured with Protein L. Table 18 shows the results from the experiment using this format. The data confirms that BPC1494 has an improved affinity for recombinant cynomolgus FcRn compared to BPC1492 at both pH6.0 and pH7.4. The fold improvement in binding affinity of BPC1494 (range 41.8-46.8 nM) for cynomolgus FcRn compared to BPC1492 (range 394-398 nM) is approximately 9-fold at pH6. It was not possible to determine the fold improvement in binding affinity at pH7.4 due to the weak binding activity of BPC1492 for FcRn. 
     
       
         
           
               
             
               
                 TABLE 17 
               
             
            
               
                   
               
               
                 Recombinant human FcRn binding affinities using the Protein L capture method 
               
            
           
           
               
               
            
               
                   
                 Affinity KD (nM) 
               
            
           
           
               
               
               
               
            
               
                   
                 BPC1492 
                 BPC1494 
                 BPC1496 
               
               
                   
                 Batch 
                 Batch 
                 Batch 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                 HEK 
                 HEK 
                 CHO clinical 
                 HEK 
                 HEK 
                 GRITS 
                 HEK 
                 HEK 
                 GRITS 
               
               
                 Expt. 
                 pH 
                 1406 
                 1348 
                 grade 
                 1407 
                 1350 
                 42954 
                 1352 
                 1408 
                 42955 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                 5 
                 6 
                 320.0  
                 325.0  
                 315.0  
                      6.08** 
                 24.9 
                 26.2 
                 14.3 
                 16.9 
                 15.4 
               
               
                   
                 7.4 
                 NAB 
                 NAB 
                 NAB 
                  2020** 
                 12600 
                 11700 
                 8980 
                 9830 
                 9670 
               
               
                 4 
                 6 
                 50.9 
                 54.8 
                 55.5 
                     1.33 
                 4.05 
                 4.50 
                 2.35 
                 3.60 
                 2.33 
               
               
                   
                 7.4 
                 NAB 
                 NAB 
                 NAB 
                  303 
                 5270 
                 4740 
                 6820 
                 7550 
                 7550 
               
               
                 3 
                 6 
                 16.0 
                 16.8 
                 17.3 
                     0.701 
                 1.960 
                 2.430 
                 2.200 
                 4.140 
                 1.810 
               
               
                   
                 7.4 
                 NAB 
                 NAB 
                 NAB 
                 1760 
                 10500 
                 10900 
                 7830 
                 8050 
                 8460 
               
               
                 2 
                 6 
                 13.1 
                 12.9 
                 13.9 
                 ## 
                 0.359 
                 0.979 
                 0.978 
                 2.440 
                 0.546 
               
               
                   
                 7.4 
                 NAB 
                 NAB 
                 NAB 
                 2010 
                 9190 
                 9330 
                 10900 
                 9480 
                 9550 
               
               
                 1 
                 6 
                 ND 
                 234   
                 ND 
                 ND 
                 66 
                 ND 
                 ND 
                 85 
                 ND 
               
               
                   
                 7.4 
                 ND 
                 NAB 
                 ND 
                 ND 
                 NAB 
                 ND 
                 ND 
                 2010 
                 ND 
               
               
                   
               
               
                 **although data points have been reported, the values should be treated with caution because these data are not consistent with the data obtained for the other batches of the same molecule during this experiment 
               
               
                 NAB = no analysable binding 
               
               
                 ND = not tested in this experiment 
               
               
                 ## = high affinity binding - beyond the sensitivity of the machine 
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 18 
               
             
            
               
                   
               
               
                 Recombinant cynomolgus FcRn binding affinities 
               
               
                 using the Protein L capture method 
               
            
           
           
               
               
               
               
               
            
               
                   
                   
                   
                 pH 6 
                 pH 7.4 
               
               
                   
                 Batch number 
                 Construct 
                 KD (nM) 
                 KD (nM) 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 GRITS44463 
                 BPC1494 
                 46.8 
                 14800 
               
               
                   
                 MCB16Marc2012 
                 BPC1494 
                 41.8 
                 13300 
               
               
                   
                 GRITS42954 
                 BPC1494 
                 43.2 
                 13700 
               
               
                   
                 Clinical grade 
                 BPC1492 
                 394 
                 No binding 
               
               
                   
                 GRITS44348 
                 BPC1492 
                 398 
                 No binding 
               
               
                   
                   
               
            
           
         
       
     
     
       
         
           
               
               
             
               
                   
                 TABLE A 
               
             
            
               
                   
                   
               
               
                   
                 Sequence identifier 
               
               
                   
                 (SEQ ID NO) 
               
            
           
           
               
               
               
            
               
                   
                 Poly- 
                 Amino 
               
               
                 Description 
                 nucleotide 
                 acid 
               
               
                   
               
            
           
           
               
               
               
            
               
                 Anti-TNF antibody light chain 
                 1 
                 2 
               
               
                 Anti-TNF antibody variable domain (VL) 
                 — 
                 3 
               
               
                 anti-TNF antibody heavy chain plus 
                 4 
                 5 
               
               
                 M252Y/S254T/T256E modification 
               
               
                 Anti-TNF antibody heavy variable domain (VH) 
                 — 
                 6 
               
               
                 IgG1 constant domain plus 
                 — 
                 7 
               
               
                 M252Y/S254T/T256E modification 
               
               
                 Anti-TNF antibody heavy chain plus 
                 8 
                 9 
               
               
                 M428L/N434S modification 
               
               
                 IgG1 constant domain plus M428L/N434S 
                 — 
                 10 
               
               
                 modification 
               
               
                 Anti-TNF antibody heavy chain (wild-type IgG1) 
                 11 
                 12 
               
               
                 IgG1 constant domain (wild-type) 
                 — 
                 13 
               
               
                 Anti-TNF antibody heavy chain plus 
                 14 
                 15 
               
               
                 T250Q/M428L modification 
               
               
                 IgG1 constant domain plus T250Q/M428L 
                 — 
                 16 
               
               
                 modification 
               
               
                 Anti-TNF antibody heavy chain plus V308F 
                 17 
                 18 
               
               
                 modification 
               
               
                 IgG1 constant domain plus V308F modification 
                 — 
                 19 
               
               
                 Anti-TNF antibody heavy chain plus V259I 
                 20 
                 21 
               
               
                 modification 
               
               
                 IgG1 constant domain plus V259I modification 
                 — 
                 22 
               
               
                 Anti-TNF antibody heavy chain plus P257L and 
                 23 
                 24 
               
               
                 N434Y variant 
               
               
                 IgG1 constant domain plus P257L and N434Y 
                 — 
                 25 
               
               
                 modification 
               
               
                 Signal peptide sequence 
                 — 
                 26 
               
               
                 Anti-TNF antibody CDRH1 
                 — 
                 27 
               
               
                 Anti-TNF antibody CDRH2 
                 — 
                 28 
               
               
                 Anti-TNF antibody CDRH3 
                 — 
                 29 
               
               
                 Anti-TNF antibody CDRL1 
                 — 
                 30 
               
               
                 Anti-TNF antibody CDRL2 
                 — 
                 31 
               
               
                 Anti-TNF antibody CDRL3 
                 — 
                 32 
               
               
                 Anti-TNF antibody CDRH1 variant 
                 — 
                 33-38 
               
               
                 Cimzia (certolizumab) LC (VL + Ck 
                   
                 39 
               
               
                 Anti-TNF antibody CDRH3 variant 
                 — 
                 40-49 
               
               
                 Anti-TNF antibody CDRL1 variant 
                 — 
                 50-61 
               
               
                 Anti-TNF antibody CDRL2 variant 
                 — 
                 62-72 
               
               
                 Anti-TNF antibody CDRL3 variant 
                 — 
                 73-76 
               
               
                 cb1-3-VH 
                 77 
                 78 
               
               
                 cb2-44-VH 
                 79 
                 80 
               
               
                 cb1-39-VH 
                 81 
                 82 
               
               
                 cb1-31-VH 
                 83 
                 84 
               
               
                 cb2-11-VH 
                 85 
                 86 
               
               
                 cb2-40-VH 
                 87 
                 88 
               
               
                 cb2-35-VH 
                 89 
                 90 
               
               
                 cb2-28-VH 
                 91 
                 92 
               
               
                 cb2-38-VH 
                 93 
                 94 
               
               
                 cb2-20-VH 
                 95 
                 96 
               
               
                 cb1-8-VL 
                 97 
                 98 
               
               
                 cb1-43-VL 
                 99 
                 100 
               
               
                 cb1-45-VL 
                 101 
                 102 
               
               
                 cb1-4-VL 
                 103 
                 104 
               
               
                 cb1-41-VL 
                 105 
                 106 
               
               
                 cb1-37-VL 
                 107 
                 108 
               
               
                 cb1-39-VL 
                 109 
                 110 
               
               
                 cb1-33-VL 
                 111 
                 112 
               
               
                 cb1-35-VL 
                 113 
                 114 
               
               
                 cb1-31-VL 
                 115 
                 116 
               
               
                 cb1-29-VL 
                 117 
                 118 
               
               
                 cb1-22-VL 
                 119 
                 120 
               
               
                 cb1-23-VL 
                 121 
                 122 
               
               
                 cb1-12-VL 
                 123 
                 124 
               
               
                 cb1-10-VL 
                 125 
                 126 
               
               
                 cb2-1-VL 
                 127 
                 128 
               
               
                 cb2-11-VL 
                 129 
                 130 
               
               
                 cb2-40-VL 
                 131 
                 132 
               
               
                 cb2-35-VL 
                 133 
                 134 
               
               
                 cb2-28-VL 
                 135 
                 136 
               
               
                 cb2-20-VL 
                 137 
                 138 
               
               
                 cb1-3-VL 
                 139 
                 140 
               
               
                 cb2-6-VL 
                 141 
                 142 
               
               
                 cb2-44-VL 
                 143 
                 144 
               
               
                 Anti-TNF antibody heavy chain variant cb1-3-VH 
                 — 
                 145 
               
               
                 plus M252Y/S254T/T256E modification 
               
               
                 Anti-TNF antibody heavy chain variant cb2-44- 
                 — 
                 146 
               
               
                 VH plus M252Y/S254T/T256E modification 
               
               
                 Anti-TNF antibody light chain variant cb1-3-VL 
                 147 
                 148 
               
               
                 Anti-TNF antibody light chain variant cb2-6-VL 
                 149 
                 150 
               
               
                 Anti-TNF antibody light chain variant cb2-44-VL 
                 151 
                 152 
               
               
                 Anti-TNF antibody heavy chain variant cb1-3-VH 
                 153 
                 154 
               
               
                 Anti-TNF antibody heavy chain variant cb2-44- 
                 155 
                 156 
               
               
                 VH 
               
               
                 Pascolizumab heavy chain containing the 
                 157 
                 158 
               
               
                 M252Y/S254T/T256E modifications 
               
               
                 Pascolizumab light chain 
                 159 
                 160 
               
               
                 Pascolizumab heavy chain 
                 — 
                 161 
               
               
                 Alternative anti-TNF antibody heavy chain plus 
                   
                 162 
               
               
                 M428L/N434S modification 
               
               
                 Alternative IgG1 constant domain plus 
                   
                 163 
               
               
                 M428L/N434S modification 
               
               
                 Anti-TNF antibody heavy chain plus 
                   
                 164 
               
               
                 H433K/N434F modification 
               
               
                 IgG1 constant domain plus H433K/N434F 
                   
                 165 
               
               
                 modification 
               
               
                 Alternative anti-TNF antibody heavy chain plus 
                   
                 166 
               
               
                 H433K/N434F modification 
               
               
                 Alternative IgG1 constant domain plus 
                   
                 167 
               
               
                 H433K/N434F modification 
               
               
                 Alternative anti-TNF antibody heavy chain plus 
                   
                 168 
               
               
                 M428L/N434S modification 
               
               
                 Alternative IgG1/2 constant domain plus 
                   
                 169 
               
               
                 M428L/N434S modification 
               
               
                 Golimumab_VH 
                   
                 170 
               
               
                 Golimumab_VL 
                   
                 171 
               
               
                 Golimumab HC 
                   
                 172 
               
               
                 Golimumab LC 
                   
                 173 
               
               
                 Remicade VH 
                   
                 174 
               
               
                 Remicade VL 
                   
                 175 
               
               
                 Remicade HC 
                   
                 176 
               
               
                 Remicade LC 
                   
                 177 
               
               
                 Cimzia (certolizumab) VH 
                   
                 178 
               
               
                 Cimzia (certolizumab) VL 
                   
                 179 
               
               
                 Cimzia (certolizumab) HC (VH + CH1) 
                   
                 180 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
            
               
                 Sequence listing 
                   
               
               
                 SEQ ID NO: 1 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody light 
                   
               
               
                 chain 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCGGGCCAGCCAGGGCATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTG 
               
               
                   
               
               
                 GCAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCACCCTGCAGAGCGGCGTGCCCAGCA 
               
               
                   
               
               
                 GATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCG 
               
               
                   
               
               
                 AGGACGTGGCCACCTACTACTGCCAGCGGTACAACAGAGCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGC 
               
               
                   
               
               
                 GATGAGCAGCTCAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCC 
               
               
                   
               
               
                 GGGAGGCCAAAGTGCAGTGGAAAGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAGA 
               
               
                   
               
               
                 GCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGA 
               
               
                   
               
               
                 GCAAGGCCGACTACGAGAAGCACAAAGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGT 
               
               
                   
               
               
                 CCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC 
               
               
                   
               
               
                 SEQ ID NO: 2 
                   
               
               
                 Protein sequence of the anti-TNF antibody light chain 
                   
               
               
                 DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA 
               
               
                   
               
               
                 SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 3 
                   
               
               
                 Protein sequence of the anti-TNF antibody variable 
                   
               
               
                 domain (VL) 
               
               
                 DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 4 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus M252Y/S254T/T256E modification 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGTACATCACCAGAGAGCC 
               
               
                   
               
               
                 CGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTG 
               
               
                   
               
               
                 GTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAA 
               
               
                   
               
               
                 CAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAA 
               
               
                   
               
               
                 GGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGC 
               
               
                   
               
               
                 AAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAG 
               
               
                   
               
               
                 CTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCG 
               
               
                   
               
               
                 CCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGC 
               
               
                   
               
               
                 TGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCA 
               
               
                   
               
               
                 GCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG 
               
               
                   
               
               
                 AAGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 5 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy chain 
                   
               
               
                 plus M252Y/S254T/T256E modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 YITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 6 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 variable domain (VH) 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 7 
                   
               
               
                 Protein sequence of the IgG1 constant domain plus 
                   
               
               
                 M252Y/S254T/T256E modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 8 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus M428L/N434S modification 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCC 
               
               
                   
               
               
                 CGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTG 
               
               
                   
               
               
                 GTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAA 
               
               
                   
               
               
                 CAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAA 
               
               
                   
               
               
                 GGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGC 
               
               
                   
               
               
                 AAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAG 
               
               
                   
               
               
                 CTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCG 
               
               
                   
               
               
                 CCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGC 
               
               
                   
               
               
                 TGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCA 
               
               
                   
               
               
                 GCAGGGCAACGTGTTCAGCTGCTCCGTGCTGCACGAGGCCCTGCACAGCCACTACACCCA 
               
               
                   
               
               
                 GAAGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 9 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain plus M428L/N434S modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 10 
                   
               
               
                 Protein sequence of the IgG1 constant domain plus 
                   
               
               
                 M428L/N434S modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 11 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain (wild-type IgG1) 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCC 
               
               
                   
               
               
                 CGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTG 
               
               
                   
               
               
                 GTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAA 
               
               
                   
               
               
                 CAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAA 
               
               
                   
               
               
                 GGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGC 
               
               
                   
               
               
                 AAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAG 
               
               
                   
               
               
                 CTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCG 
               
               
                   
               
               
                 CCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGC 
               
               
                   
               
               
                 TGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCA 
               
               
                   
               
               
                 GCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG 
               
               
                   
               
               
                 AAGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 12 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain (wild-type IgG1) 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 13 
                   
               
               
                 Protein sequence of the IgG1 constant domain 
                   
               
               
                 (wild-type) 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 14 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus T250Q/M428L modification 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACcaaCTGATGATCAGCAGAACCCCC 
               
               
                   
               
               
                 GAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGT 
               
               
                   
               
               
                 ACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACA 
               
               
                   
               
               
                 GCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGG 
               
               
                   
               
               
                 AGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAA 
               
               
                   
               
               
                 GGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCT 
               
               
                   
               
               
                 GACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCC 
               
               
                   
               
               
                 GTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTG 
               
               
                   
               
               
                 GACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGC 
               
               
                   
               
               
                 AGGGCAACGTGTTCAGCTGCTCCGTGtTGCACGAGGCCCTGCACAATCACTACACCCAGAA 
               
               
                   
               
               
                 GAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 15 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain plus T250Q/M428L modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDQL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 16 
                   
               
               
                 Protein sequence of the IgG1 constant domain plus 
                   
               
               
                 T250Q/M428L modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDQLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHNHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 17 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus V308F modification 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCC 
               
               
                   
               
               
                 CGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTG 
               
               
                   
               
               
                 GTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAA 
               
               
                   
               
               
                 CAGCACCTACCGGGTGGTGTCCGTGCTGACCtTcCTGCACCAGGATTGGCTGAACGGCAAG 
               
               
                   
               
               
                 GAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCA 
               
               
                   
               
               
                 AGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGC 
               
               
                   
               
               
                 TGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGC 
               
               
                   
               
               
                 CGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCT 
               
               
                   
               
               
                 GGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAG 
               
               
                   
               
               
                 CAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGA 
               
               
                   
               
               
                 AGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 18 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain plus V308F modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTFLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 19 
                   
               
               
                 Protein sequence of the IgG1 constant domains plus 
                   
               
               
                 V308F modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTFLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 20 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus V259I modification 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCC 
               
               
                   
               
               
                 CGAGATCACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAAGTGAAGTTCAACTGG 
               
               
                   
               
               
                 TACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAAC 
               
               
                   
               
               
                 AGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAG 
               
               
                   
               
               
                 GAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCA 
               
               
                   
               
               
                 AGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGC 
               
               
                   
               
               
                 TGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGC 
               
               
                   
               
               
                 CGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCT 
               
               
                   
               
               
                 GGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAG 
               
               
                   
               
               
                 CAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGA 
               
               
                   
               
               
                 AGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 21 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain plus V259I modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEITCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN 
               
               
                   
               
               
                 GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 22 
                   
               
               
                 Protein sequence of the IgG1 constant domains 
                   
               
               
                 plus V259I modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEITCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 23 
                   
               
               
                 Polynucleotide sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus P257L and N434Y variant 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCT 
               
               
                   
               
               
                 GGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTG 
               
               
                   
               
               
                 GTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAA 
               
               
                   
               
               
                 CAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAA 
               
               
                   
               
               
                 GGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGC 
               
               
                   
               
               
                 AAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAG 
               
               
                   
               
               
                 CTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCG 
               
               
                   
               
               
                 CCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGC 
               
               
                   
               
               
                 TGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCA 
               
               
                   
               
               
                 GCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACTATCACTACACCCAG 
               
               
                   
               
               
                 AAGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 24 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain plus P257L and N434Y modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTLEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 25 
                   
               
               
                 Protein sequence of the IgG1 constant domains plus 
                   
               
               
                 P257L and N434Y modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTLEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 26 
                   
               
               
                 Signal peptide sequence 
                   
               
               
                 MGWSCIILFLVATATGVHS 
               
               
                   
               
               
                 SEQ ID NO: 27 
                   
               
               
                 anti-TNF antibody CDRH1 
                   
               
               
                 DYAMH 
               
               
                   
               
               
                 SEQ ID NO: 28 
                   
               
               
                 anti-TNF antibody CDRH2 
                   
               
               
                 AITWNSGHIDYADSVEG 
               
               
                   
               
               
                 SEQ ID NO: 29 
                   
               
               
                 anti-TNF antibody CDRH3 
                   
               
               
                 VSYLSTASSLDY 
               
               
                   
               
               
                 SEQ ID NO: 30 
                   
               
               
                 anti-TNF antibody CDRL1 
                   
               
               
                 RASQGIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 31 
                   
               
               
                 anti-TNF antibody CDRL2 
                   
               
               
                 AASTLQS 
               
               
                   
               
               
                 SEQ ID NO: 32 
                   
               
               
                 anti-TNF antibody CDRL3 
                   
               
               
                 QRYNRAPYT 
               
               
                   
               
               
                 SEQ ID NO: 33 
                   
               
               
                 anti-TNF antibody CDRH1 variant 
                   
               
               
                 QYAMH 
               
               
                   
               
               
                 SEQ ID NO: 34 
                   
               
               
                 anti-TNF antibody CDRH1 variant 
                   
               
               
                 HYALH 
               
               
                   
               
               
                 SEQ ID NO: 35 
                   
               
               
                 anti-TNF antibody CDRH1 variant 
                   
               
               
                 HYAMH 
               
               
                   
               
               
                 SEQ ID NO: 36 
                   
               
               
                 anti-TNF antibody CDRH1 variant 
                   
               
               
                 QHALH 
               
               
                   
               
               
                 SEQ ID NO: 37 
                   
               
               
                 anti-TNF antibody CDRH1 variant 
                   
               
               
                 QHAMH 
               
               
                   
               
               
                 SEQ ID NO: 38 
                   
               
               
                 anti-TNF antibody CDRH1 variant 
                   
               
               
                 DHALH 
               
               
                   
               
               
                 SEQ ID NO: 39 
                   
               
               
                 Cimzia (certolizumab) LC (VL + Ck) 
                   
               
               
                 DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSG 
               
               
                   
               
               
                 SGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA 
               
               
                   
               
               
                 SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 40 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VHYLSTASQLHH 
               
               
                   
               
               
                 SEQ ID NO: 41 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VQYLSTASSLQS 
               
               
                   
               
               
                 SEQ ID NO: 42 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VKYLSTASSLHY 
               
               
                   
               
               
                 SEQ ID NO: 43 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VKYLSTASNLES 
               
               
                   
               
               
                 SEQ ID NO: 44 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VHYLSTASSLDY 
               
               
                   
               
               
                 SEQ ID NO: 45 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VSYLSTASSLQS 
               
               
                   
               
               
                 SEQ ID NO: 46 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VRYLSTASNLQH 
               
               
                   
               
               
                 SEQ ID NO: 47 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VQYLSTASQLHS 
               
               
                   
               
               
                 SEQ ID NO: 48 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VRYLSTASQLDY 
               
               
                   
               
               
                 SEQ ID NO: 49 
                   
               
               
                 anti-TNF antibody CDRH3 variant 
                   
               
               
                 VRYLSTASSLDY 
               
               
                   
               
               
                 SEQ ID NO: 50 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASKKIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 51 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASRKLRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 52 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASRRLRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 53 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASKRIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 54 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASRKIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 55 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASRRIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 56 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASREIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 57 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASQGIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 58 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASQKIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 59 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 RASRGLRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 60 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 HASQRIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 61 
                   
               
               
                 anti-TNF antibody CDRL1 variant 
                   
               
               
                 RASRRIRNYLA 
               
               
                   
               
               
                 SEQ ID NO: 62 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLLR 
               
               
                   
               
               
                 SEQ ID NO: 63 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLLK 
               
               
                   
               
               
                 SEQ ID NO: 64 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLLP 
               
               
                   
               
               
                 SEQ ID NO: 65 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLQP 
               
               
                   
               
               
                 SEQ ID NO: 66 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLLH 
               
               
                   
               
               
                 SEQ ID NO: 67 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSFLP 
               
               
                   
               
               
                 SEQ ID NO: 68 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLLQ 
               
               
                   
               
               
                 SEQ ID NO: 69 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLQQ 
               
               
                   
               
               
                 SEQ ID NO: 70 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASTLLK 
               
               
                   
               
               
                 SEQ ID NO: 71 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLQN 
               
               
                   
               
               
                 SEQ ID NO: 72 
                   
               
               
                 anti-TNF antibody CDRL2 variant 
                   
               
               
                 AASSLQK 
               
               
                   
               
               
                 SEQ ID NO: 73 
                   
               
               
                 anti-TNF antibody CDRL3 variant 
                   
               
               
                 QRYDRPPYT 
               
               
                   
               
               
                 SEQ ID NO: 74 
                   
               
               
                 anti-TNF antibody CDRL3 variant 
                   
               
               
                 QRYDKPPYT 
               
               
                   
               
               
                 SEQ ID NO: 75 
                   
               
               
                 anti-TNF antibody CDRL3 variant 
                   
               
               
                 QRYNRPPYT 
               
               
                   
               
               
                 SEQ ID NO: 76 
                   
               
               
                 anti-TNF antibody CDRL3 variant 
                   
               
               
                 QRYNKPPYT 
               
               
                   
               
               
                 SEQ ID NO: 77 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb1-3-VH 
               
               
                 (aka cb2-6-VH) 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 78 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb1-3-VH (aka cb2-6-VH) 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 79 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-44-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACCACGCCCTGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGAG 
               
               
                   
               
               
                 GTACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTC 
               
               
                   
               
               
                 CAGC 
               
               
                   
               
               
                 SEQ ID NO: 80 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-44-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHALHWVRQAPGKGLEWVSAITWNSGHIDYADS 
               
               
                   
               
               
                 VEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVRYLSTASSLDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 81 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb1-39-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCACTACGCCCTGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 82 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb1-39-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDHYALHWVRQAPGKGLEWVSAITWNSGHIDYADS 
               
               
                   
               
               
                 VEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 83 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb1-31-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGCAC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCCAACTGCACCACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 84 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb1-31-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVHYLSTASQLHHWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 85 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-11-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCACTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGCA 
               
               
                   
               
               
                 GTACCTGAGCACCGCCAGCAGCCTGCAGAGCTGGGGCCAGGGCACACTAGTGACCGTGTC 
               
               
                   
               
               
                 CAGC 
               
               
                   
               
               
                 SEQ ID NO: 86 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-11-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDHYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVQYLSTASSLQSWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 87 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-40-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGAAG 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGCACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 88 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-40-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVKYLSTASSLHYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 89 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-35-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGCACGCCCTGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGCAC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 90 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-35-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQHALHWVRQAPGKGLEWVSAITWNSGHIDYADS 
               
               
                   
               
               
                 VEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVHYLSTASSLDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 91 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-28-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGCAC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCCAGCTGCACCACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 92 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-28-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVHYLSTASQLHHWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 93 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-38-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGCACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 94 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-38-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQHAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 95 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable heavy domain variant cb2-20-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGAAG 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAACCTGGAGAGCTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGC 
               
               
                   
               
               
                 SEQ ID NO: 96 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 heavy domain variant cb2-20-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVKYLSTASNLESWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 97 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-8-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAAGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAGGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 98 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-8-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASKKIRNYLAWYQQKPGKAPKLLIYAASSLLRGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 99 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-43-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 100 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-43-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKLRNYLAWYQQKPGKAPKLLIYAASSLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 101 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-45-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 102 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-45-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRLRNYLAWYQQKPGKAPKLLIYAASSLLPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 103 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-4-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAGGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 104 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-4-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKLRNYLAWYQQKPGKAPKLLIYAASSLLRGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 105 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-41-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAAGAGGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAAGCCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 106 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-41-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASKRIRNYLAWYQQKPGKAPKLLIYAASSLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDKPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 107 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-37-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAGGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACAACAGACCCCCTTACACCTTCGGCCAGGGC 
               
               
                   
               
               
                 ACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 108 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-37-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKLRNYLAWYQQKPGKAPKLLIYAASSLLRGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 109 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-39-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 110 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-39-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKIRNYLAWYQQKPGKAPKLLIYAASSLQPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 111 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-33-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCACGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 112 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-33-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRIRNYLAWYQQKPGKAPKLLIYAASSLLHGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 113 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-35-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 114 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-35-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRLRNYLAWYQQKPGKAPKLLIYAASSLQPGVPSRFSG 
               
               
                   
               
               
                 SGSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 115 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-31-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACAACAAGCCCCCTTACACCTTCGGCCAGGGC 
               
               
                   
               
               
                 ACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 116 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-31-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRLRNYLAWYQQKPGKAPKLLIYAASSLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNKPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 117 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-29-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCTTCCTGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 118 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-29-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKIRNYLAWYQQKPGKAPKLLIYAASSFLPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 119 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-22-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAAGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 120 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-22-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASKKIRNYLAWYQQKPGKAPKLLIYAASSLQPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 121 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-23-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 122 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-23-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRIRNYLAWYQQKPGKAPKLLIYAASSLLQGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 123 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-12-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGCAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 124 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-12-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKLRNYLAWYQQKPGKAPKLLIYAASSLQQGVPSRFSG 
               
               
                   
               
               
                 SGSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 125 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-10-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 126 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-10-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKLRNYLAWYQQKPGKAPKLLIYAASSLLPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 127 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-1-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGGAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 128 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-1-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASREIRNYLAWYQQKPGKAPKLLIYAASSLLPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 129 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-11-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCCAGGGCATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCACCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 130 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-11-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASQGIRNYLAWYQQKPGKAPKLLIYAASTLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 131 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-40-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCCAGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCAGCAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 132 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-40-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASQKIRNYLAWYQQKPGKAPKLLIYAASSLQQGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 133 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-35-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCACGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 134 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-35-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRLRNYLAWYQQKPGKAPKLLIYAASSLLHGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 135 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-28-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAGGCTGAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 136 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-28-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRRLRNYLAWYQQKPGKAPKLLIYAASSLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 137 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-20-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAAGAGGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAGGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACAACAAGCCCCCTTACACCTTCGGCCAGGGC 
               
               
                   
               
               
                 ACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 138 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-20-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASKRIRNYLAWYQQKPGKAPKLLIYAASSLLRGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNKPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 139 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb1-3-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAGGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAAGCCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 140 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb1-3-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKIRNYLAWYQQKPGKAPKLLIYAASSLLRGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDKPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 141 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-6-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAAGAGGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACAACAAGCCCCCTTACACCTTCGGCCAGGGC 
               
               
                   
               
               
                 ACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 142 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-6-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASKRIRNYLAWYQQKPGKAPKLLIYAASSLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNKPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 143 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody 
                   
               
               
                 variable light domain variant cb2-44-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACG 
               
               
                   
               
               
                 SEQ ID NO: 144 
                   
               
               
                 Protein sequence of anti-TNF antibody variable 
                   
               
               
                 light domain variant cb2-44-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKIRNYLAWYQQKPGKAPKLLIYAASSLLPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 145 
                   
               
               
                 Protein sequence of anti-TNF antibody heavy chain 
                   
               
               
                 variant cb1-3-VH plus M252Y/S254T/T256E modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 YITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 146 
                   
               
               
                 Protein sequence of anti-TNF antibody heavy chain 
                   
               
               
                 variant cb2-44-VH plus M252Y/S254T/T256E modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHALHWVRQAPGKGLEWVSAITWNSGHIDYADS 
               
               
                   
               
               
                 VEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVRYLSTASSLDYWGQGTLVTVSSASTKGP 
               
               
                   
               
               
                 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT 
               
               
                   
               
               
                 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLY 
               
               
                   
               
               
                 ITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN 
               
               
                   
               
               
                 GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 147 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody light 
                   
               
               
                 chain variant cb1-3-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAGGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAAGCCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGC 
               
               
                   
               
               
                 GATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCC 
               
               
                   
               
               
                 GGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGA 
               
               
                   
               
               
                 GCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGA 
               
               
                   
               
               
                 GCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGT 
               
               
                   
               
               
                 CCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC 
               
               
                   
               
               
                 SEQ ID NO: 148 
                   
               
               
                 Protein sequence of anti-TNF antibody light chain 
                   
               
               
                 variant cb1-3-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKIRNYLAWYQQKPGKAPKLLIYAASSLLRGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDKPPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA 
               
               
                   
               
               
                 SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 149 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody light 
                   
               
               
                 chain variant cb2-6-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAAGAGGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGAAGGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACAACAAGCCCCCTTACACCTTCGGCCAGGGC 
               
               
                   
               
               
                 ACCAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGC 
               
               
                   
               
               
                 GATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCC 
               
               
                   
               
               
                 GGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGA 
               
               
                   
               
               
                 GCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGA 
               
               
                   
               
               
                 GCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGT 
               
               
                   
               
               
                 CCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC 
               
               
                   
               
               
                 SEQ ID NO: 150 
                   
               
               
                 Protein sequence of anti-TNF antibody light chain 
                   
               
               
                 variant cb2-6-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASKRIRNYLAWYQQKPGKAPKLLIYAASSLLKGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYNKPPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA 
               
               
                   
               
               
                 SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 151 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody light 
                   
               
               
                 chain variant cb2-44-VL 
               
               
                 GATATCCAGATGACCCAGAGCCCCAGCAGCCTGAGCGCCTCTGTGGGCGATAGAGTGACCA 
               
               
                   
               
               
                 TCACCTGCCACGCCAGCAGGAAGATCAGAAACTACCTGGCCTGGTATCAGCAGAAGCCTGG 
               
               
                   
               
               
                 CAAGGCCCCTAAGCTGCTGATCTACGCCGCCAGCAGCCTGCTGCCCGGCGTGCCCAGCAG 
               
               
                   
               
               
                 ATTCAGCGGCAGCGGCTCCGGCACCGACTTCACCCTGACCATCAGCAGCCTGCAGCCCGA 
               
               
                   
               
               
                 GGACGTGGCCACCTACTACTGCCAGCGGTACGACAGACCCCCTTACACCTTCGGCCAGGG 
               
               
                   
               
               
                 CACCAAGGTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGC 
               
               
                   
               
               
                 GATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCC 
               
               
                   
               
               
                 GGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGA 
               
               
                   
               
               
                 GCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGA 
               
               
                   
               
               
                 GCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGT 
               
               
                   
               
               
                 CCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC 
               
               
                   
               
               
                 SEQ ID NO: 152 
                   
               
               
                 Protein sequence of anti-TNF antibody light chain 
                   
               
               
                 variant cb2-44-VL 
               
               
                 DIQMTQSPSSLSASVGDRVTITCHASRKIRNYLAWYQQKPGKAPKLLIYAASSLLPGVPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLQPEDVATYYCQRYDRPPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTA 
               
               
                   
               
               
                 SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 153 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody heavy 
                   
               
               
                 chain variant cb1-3-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACCAGTACGCCATGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGTCC 
               
               
                   
               
               
                 TACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCC 
               
               
                   
               
               
                 AGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGC 
               
               
                   
               
               
                 GGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTG 
               
               
                   
               
               
                 TCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGC 
               
               
                   
               
               
                 AGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAG 
               
               
                   
               
               
                 ACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGC 
               
               
                   
               
               
                 CCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAG 
               
               
                   
               
               
                 GCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCC 
               
               
                   
               
               
                 CGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTG 
               
               
                   
               
               
                 GTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAA 
               
               
                   
               
               
                 CAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAA 
               
               
                   
               
               
                 GGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGC 
               
               
                   
               
               
                 AAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAG 
               
               
                   
               
               
                 CTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCG 
               
               
                   
               
               
                 CCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGC 
               
               
                   
               
               
                 TGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCA 
               
               
                   
               
               
                 GCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAG 
               
               
                   
               
               
                 AAGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 154 
                   
               
               
                 Protein sequence of anti-TNF antibody heavy chain 
                   
               
               
                 variant cb1-3-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDQYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 155 
                   
               
               
                 Polynucleotide sequence of anti-TNF antibody heavy 
                   
               
               
                 chain variant cb2-44-VH 
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTGCAGCCCGGCAGAAGCCTGAGACT 
               
               
                   
               
               
                 GAGCTGTGCCGCCAGCGGCTTCACCTTCGACGACCACGCCCTGCACTGGGTGAGGCAGGC 
               
               
                   
               
               
                 CCCTGGCAAGGGCCTGGAGTGGGTGTCCGCCATCACCTGGAATAGCGGCCACATCGACTA 
               
               
                   
               
               
                 CGCCGACAGCGTGGAGGGCAGATTCACCATCAGCCGGGACAACGCCAAGAACAGCCTGTA 
               
               
                   
               
               
                 CCTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAAGGTGAG 
               
               
                   
               
               
                 GTACCTGAGCACCGCCAGCAGCCTGGACTACTGGGGCCAGGGCACACTAGTGACCGTGTC 
               
               
                   
               
               
                 CAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAG 
               
               
                   
               
               
                 CGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGT 
               
               
                   
               
               
                 GTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAG 
               
               
                   
               
               
                 CAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCA 
               
               
                   
               
               
                 GACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAG 
               
               
                   
               
               
                 CCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGA 
               
               
                   
               
               
                 GGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCC 
               
               
                   
               
               
                 CCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACT 
               
               
                   
               
               
                 GGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACA 
               
               
                   
               
               
                 ACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCA 
               
               
                   
               
               
                 AGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAG 
               
               
                   
               
               
                 CAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGA 
               
               
                   
               
               
                 GCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATC 
               
               
                   
               
               
                 GCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTG 
               
               
                   
               
               
                 CTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGC 
               
               
                   
               
               
                 AGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCA 
               
               
                   
               
               
                 GAAGAGCCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 156 
                   
               
               
                 Protein sequence of anti-TNF antibody heavy chain 
                   
               
               
                 variant cb2-44-VH 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHALHWVRQAPGKGLEWVSAITWNSGHIDYADS 
               
               
                   
               
               
                 VEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVRYLSTASSLDYWGQGTLVTVSSASTKGP 
               
               
                   
               
               
                 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT 
               
               
                   
               
               
                 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 157 
                   
               
               
                 Polynucleotide sequence of pascolizumab heavy chain 
                   
               
               
                 containing the M252Y/S254T/T256E modifications 
               
               
                 CAGGTGACCCTGAGGGAGAGCGGCCCCGCCCTGGTGAAGCCCACCCAGACCCTGACCCTG 
               
               
                   
               
               
                 ACCTGCACCTTCAGCGGCTTTAGCCTCAGCACCTCCGGCATGGGCGTGAGCTGGATCAGGC 
               
               
                   
               
               
                 AGCCACCCGGCAAAGGCCTGGAGTGGCTGGCCCACATCTACTGGGACGACGACAAGAGGT 
               
               
                   
               
               
                 ACAACCCCAGCCTGAAGAGCCGGCTGACCATCAGCAAGGATACCAGCAGGAACCAGGTGG 
               
               
                   
               
               
                 TGCTGACCATGACCAACATGGACCCCGTGGACACCGCTACCTACTACTGCGCCAGGAGGGA 
               
               
                   
               
               
                 GACCGTCTTCTACTGGTACTTCGACGTGTGGGGAAGGGGCACACTAGTGACCGTGTCCAGC 
               
               
                   
               
               
                 GCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGC 
               
               
                   
               
               
                 GGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCC 
               
               
                   
               
               
                 TGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGC 
               
               
                   
               
               
                 GGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACC 
               
               
                   
               
               
                 TACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCA 
               
               
                   
               
               
                 AGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCC 
               
               
                   
               
               
                 CCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGtacATCacCAGAgagCCCGAGG 
               
               
                   
               
               
                 TGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGT 
               
               
                   
               
               
                 GGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCAC 
               
               
                   
               
               
                 CTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTA 
               
               
                   
               
               
                 CAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCC 
               
               
                   
               
               
                 AAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACC 
               
               
                   
               
               
                 AAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGG 
               
               
                   
               
               
                 AGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACA 
               
               
                   
               
               
                 GCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGG 
               
               
                   
               
               
                 GCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAG 
               
               
                   
               
               
                 CCTGAGCCTGTCCCCTGGCAAG 
               
               
                   
               
               
                 SEQ ID NO: 158 
                   
               
               
                 Protein sequence of pascolizumab heavy chain 
                   
               
               
                 containing the M252Y/S254T/T256E modifications 
               
               
                 QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPS 
               
               
                   
               
               
                 LKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPS 
               
               
                   
               
               
                 VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV 
               
               
                   
               
               
                 PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYI 
               
               
                   
               
               
                 TREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG 
               
               
                   
               
               
                 KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW 
               
               
                   
               
               
                 ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS 
               
               
                   
               
               
                 PGK 
               
               
                   
               
               
                 SEQ ID NO: 159 
                   
               
               
                 Polynucleotide sequence of pascolizumab light chain 
                   
               
               
                 GACATCGTGCTGACCCAGAGCCCCTCTTCCCTGAGCGCAAGCGTGGGCGATAGGGTGACC 
               
               
                   
               
               
                 ATCACCTGCAAGGCCAGCCAGAGCGTGGACTACGACGGCGACAGCTACATGAACTGGTACC 
               
               
                   
               
               
                 AGCAGAAGCCCGGCAAGGCCCCCAAACTGCTGATCTACGCCGCCAGCAACCTCGAGTCAG 
               
               
                   
               
               
                 GCATTCCCAGCAGGTTTAGCGGCAGCGGCAGCGGCACCGACTTCACCTTCACAATCAGCAG 
               
               
                   
               
               
                 CCTGCAGCCCGAGGACATCGCCACCTACTACTGCCAGCAGAGCAACGAGGACCCTCCCAC 
               
               
                   
               
               
                 CTTCGGACAGGGCACCAAGGTCGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCAT 
               
               
                   
               
               
                 CTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAA 
               
               
                   
               
               
                 CAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGG 
               
               
                   
               
               
                 CAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAG 
               
               
                   
               
               
                 CACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGAC 
               
               
                   
               
               
                 CCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC 
               
               
                   
               
               
                 SEQ ID NO: 160 
                   
               
               
                 Protein sequence of pascolizumab light chain 
                   
               
               
                 DIVLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSR 
               
               
                   
               
               
                 FSGSGSGTDFTFTISSLQPEDIATYYCQQSNEDPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS 
               
               
                   
               
               
                 GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK 
               
               
                   
               
               
                 VYACEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 161 
                   
               
               
                 Protein sequence of pascolizumab heavy chain 
                   
               
               
                 QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPS 
               
               
                   
               
               
                 LKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGRGTLVTVSSASTKGPS 
               
               
                   
               
               
                 VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV 
               
               
                   
               
               
                 PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI 
               
               
                   
               
               
                 SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG 
               
               
                   
               
               
                 KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW 
               
               
                   
               
               
                 ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS 
               
               
                   
               
               
                 PGK 
               
               
                   
               
               
                 SEQ ID NO: 162 
                   
               
               
                 Alternative protein sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus M428L/N434S modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV 
               
               
                   
               
               
                 EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLS 
               
               
                   
               
               
                 LSPGK 
               
               
                   
               
               
                 SEQ ID NO: 163 
                   
               
               
                 Alternative protein sequence of the IgG1 constant 
                   
               
               
                 domain plus M428L/N434S modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP 
               
               
                   
               
               
                 SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYT 
               
               
                   
               
               
                 QKSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 164 
                   
               
               
                 Protein sequence of the anti-TNF antibody heavy 
                   
               
               
                 chain plus H433K/N434F modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 165 
                   
               
               
                 Protein sequence of the IgG1 constant domain plus 
                   
               
               
                 H433K/N434F modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 166 
                   
               
               
                 Alternative protein sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus H433K/N434F modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV 
               
               
                   
               
               
                 EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLS 
               
               
                   
               
               
                 LSPGK 
               
               
                   
               
               
                 SEQ ID NO: 167 
                   
               
               
                 Alternative protein sequence of the IgG1 constant 
                   
               
               
                 domain plus H433K/N434F modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPK 
               
               
                   
               
               
                 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH 
               
               
                   
               
               
                 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP 
               
               
                   
               
               
                 SDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYT 
               
               
                   
               
               
                 QKSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 168 
                   
               
               
                 Alternative protein sequence of the anti-TNF antibody 
                   
               
               
                 heavy chain plus M428L/N434S modification 
               
               
                 EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYAD 
               
               
                   
               
               
                 SVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKG 
               
               
                   
               
               
                 PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV 
               
               
                   
               
               
                 TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPVAGPSVFLFPPKPKDTL 
               
               
                   
               
               
                 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWL 
               
               
                   
               
               
                 NGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV 
               
               
                   
               
               
                 EWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLS 
               
               
                   
               
               
                 LSPGK 
               
               
                   
               
               
                 SEQ ID NO: 169 
                   
               
               
                 Alternative protein sequence of the IgG1/2 constant 
                   
               
               
                 domain plus M428L/N434S modification 
               
               
                 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS 
               
               
                   
               
               
                 LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPPVAGPSVFLFPPKP 
               
               
                   
               
               
                 KDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQ 
               
               
                   
               
               
                 DWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS 
               
               
                   
               
               
                 DIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQ 
               
               
                   
               
               
                 KSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 170 
                   
               
               
                 Golimumab_VH 
                   
               
               
                 QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYAD 
               
               
                   
               
               
                 SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVS 
               
               
                   
               
               
                 S 
               
               
                   
               
               
                 SEQ ID NO: 171 
                   
               
               
                 Golimumab_VL 
                   
               
               
                 EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIKRT 
               
               
                   
               
               
                 SEQ ID NO: 172 
                   
               
               
                 Golimumab_HC 
                   
               
               
                 QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYAD 
               
               
                   
               
               
                 SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVS 
               
               
                   
               
               
                 SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY 
               
               
                   
               
               
                 SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP 
               
               
                   
               
               
                 KPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL 
               
               
                   
               
               
                 HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY 
               
               
                   
               
               
                 PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY 
               
               
                   
               
               
                 TQKSLSLSPGK 
               
               
                   
               
               
                 SEQ ID NO: 173 
                   
               
               
                 Golimumab_LC 
                   
               
               
                 EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGS 
               
               
                   
               
               
                 GSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGT 
               
               
                   
               
               
                 ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 174 
                   
               
               
                 Remicade_VH 
                   
               
               
                 EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYA 
               
               
                   
               
               
                 ESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS 
               
               
                   
               
               
                 SEQ ID NO: 175 
                   
               
               
                 Remicade_VL 
                   
               
               
                 DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVKRT 
               
               
                   
               
               
                 SEQ ID NO: 176 
                   
               
               
                 Remicade_HC 
                   
               
               
                 EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYA 
               
               
                   
               
               
                 ESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSSASTKGP 
               
               
                   
               
               
                 SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT 
               
               
                   
               
               
                 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLY 
               
               
                   
               
               
                 ITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN 
               
               
                   
               
               
                 GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 
               
               
                   
               
               
                 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL 
               
               
                   
               
               
                 SPGK 
               
               
                   
               
               
                 SEQ ID NO: 177 
                   
               
               
                 Remicade_LC 
                   
               
               
                 DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGS 
               
               
                   
               
               
                 GSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVKRTVAAPSVFIFPPSDEQLKSGTA 
               
               
                   
               
               
                 SVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA 
               
               
                   
               
               
                 CEVTHQGLSSPVTKSFNRGEC 
               
               
                   
               
               
                 SEQ ID NO: 178 
                   
               
               
                 Cimzia (certolizumab) VH 
                   
               
               
                 EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYAD 
               
               
                   
               
               
                 SVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS 
               
               
                   
               
               
                 SEQ ID NO: 179 
                   
               
               
                 Cimzia (certolizumab) VL 
                   
               
               
                 DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSG 
               
               
                   
               
               
                 SGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRT 
               
               
                   
               
               
                 SEQ ID NO: 180 
                   
               
               
                 Cimzia (certolizumab) HC (VH + CH1) 
                   
               
               
                 EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYAD 
               
               
                   
               
               
                 SVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSSASTKGPS 
               
               
                   
               
               
                 VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV 
               
               
                   
               
               
                 PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA